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Miniaturization technologies have developed rapidly over the past decade. 
However, the challenge in advancing miniaturization strategies largely depends on their 
scalability to cater to a myriad of important applications. There is an increasing demand 
for the accurate processing of scarce samples, such as stem cells, cancer stem cells and 
patients’ samples. Miniaturization technologies may offer important insights into the 
characterization of these biologically relevant samples for research and clinical 
applications.   
This thesis presents a novel miniaturized assay technology, DropArrayTM, for 
conducting heterogeneous cell-based assays. The DropArrayTM plate consists of an array 
of 2-mm hydrophilic spots, insulated from each other by a hydrophobic 
polytetrafluoroethylene (PTFE) coating. Each spot represents a 2-ml assay. DropArrayTM 
Accelerator has been designed to reproducibly automate the precise movements and 
fluidics during parallel rinsing so that there is negligible cross-contamination between the 
assay points on each plate.  
DropArrayTM has been successfully employed to miniaturize a wide range of 
heterogeneous assays, such as enzyme-linked immunosorbent assay (ELISA) and high-
content screening (HCS) cell-based assays. Besides ensuring the robustness of this 
technology for HCS assays, effects of miniaturization have been studied in detail. HCS 
assays are shown to remain robust at 2 ml, using only 500 cells per data point. Applying 
DropArrayTM to HCS assays also reduces the antibody staining time significantly by ~ 
60%. 
DropArrayTM has also been applied to study the drug responses of various scarce 
cancer side population (SP) phenotypes. Interesting drug resistance phenomena that have 
been difficult to demonstrate have been successfully elucidated in this work. The SP 
phenotypes enriched from various cell lines are associated with cancer stem cell 
properties in the literature. Besides showing increased expressions of genes associated 
with drug efflux capabilities, these cells have been found to initiate an entire tumor with 
only 3000 cells. In vitro drug response assays with these scarce cells have been 
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Chapter 1 – Background and Motivation 
 
1.1 The Promise of Assay Miniaturization 
The past 20 years of assay miniaturization has led to the development of many 
exciting biological applications [1–3]. For example, 6 years ago, genetic sequencing 
of the human genome used to take hundreds of biologists over 13 years; but now, it 
can be accomplished by three technicians in 1 week using a microfluidic platform [4]. 
In addition, the amount of sample that was barely enough for a single gene expression 
study by polymerase chain reaction (PCR) years ago is now sufficient for screening 
against 60,000 genes on a single microarray platform [5]. Even the laborious Western 
blotting on polyacrylamide gel can be miniaturized on a capillary microfluidic 
platform to save time, cost and samples, without affecting the robustness of the assay 
[6]. These examples demonstrated the utmost importance of miniaturization 
technologies, which have facilitated the continued advances in biological research.  
According to Wölcke et al., miniaturization of assays refers to the reduction of 
96-well plates assays to volumes below 10 ml [7]. To date, there are a myriad of 
different miniaturization assay platforms that have been developed. Based on their 
complexity and capabilities in liquid handling, we have classified them into 3 assay 
platforms: (i) miniaturized well plates, (ii) array platforms, and (iii) microfluidic 
platforms. The miniaturized well plates consist of smaller walled wells to reduce 
assay volume [8–9]. The array platforms allow assays to be conducted on flat 
functionalized surfaces with virtual wells to isolate the individual assays [10–13]. The 
microfluidic platforms consist of a network of microchannels for fluidics control [14–
18]. The advantages and disadvantages of these three platforms are summarized in 
Table 1.1.  
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The micro-well chip and 1536-well plates are probably the most simplified 
and straight-forward miniaturization approach. They are accomplished by scaling 
down the well dimensions of the conventional well plates. Such platforms are of 
particularly great interest in the 1990’s because of the application of enzymatic assays 
for high-throughput screening (HTS) [19]. Since these assays are mainly addition-
based (homogeneous) assays, miniaturization does not require sophisticated liquid 
handling capabilities to aspirate tiny volumes of reagent from the well for rinsing. 
However, in the 21st century, with the rising trend to conduct more biologically 
relevant heterogeneous assays such as enzyme-linked immunosorbent assay (ELISA) 
and high-content cell-based assays [20], the microwell platforms has not quite kept up 
with the requirements of heterogeneous assays. Nevertheless, there have been some 
successes in conducting heterogeneous assays on the 1536-well platform. Notably, the 
development of the epiKTM has allowed for the screening of 1 million ELISA’s for 
HTS [21].  
Since heterogeneous assays require multiple rinsing steps in the experiment, 
the ability to conduct miniaturized assays using array platforms (on a flat slide 
containing an array of virtual wells) has become an attractive solution to the problems 
faced by microwell users [22]. The virtual well design on microarrays facilitates 
access to all the data points in a single parallel rinse. This simplifies the design of the 
platform, thus reducing its cost of manufacturing. The microarray technology is 
probably one of the most commercially viable miniaturization techniques because of 
its simplicity for manufacturing and ease of use [23]. With the early commercial 
products revolving around the applications of DNA microarrays [24], the microarray 
technology has, in the recent years, evolved to include applications targeting proteins, 
antibodies and tissues [11–13, 25]. Furthermore, microarray technology has been 
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applied to a range of heterogeneous assays, including ELISA and HCS assays [26–27]. 
However, one of the major pitfalls in the microarray platform is that the patterned 
surface loses its selective hydrophobic-hydrophilic characteristics after repeated 
rinsing due to surface wetting [28]. Thus, cross-contamination between the 
neighboring spots needs to be accounted for when applying the array platforms. 
Furthermore, conducting heterogeneous assays on the array platforms may be more 
challenging as compared to that on the microfluidics platform, since the continuous 
flow-through rinsing technique used in the array platforms may result in less control 
of the individual spots.  
Among the three different platforms, the microfluidics platform is probably 
the most versatile for the miniaturization of heterogeneous assays [29]. Despite its 
complexity in terms of design and fabrication, the microfluidics platform is the most 
flexible in terms of adapting to the liquid handling requirements of an assay [30–32]. 
Unfortunately, each designed microfluidic platform can only cater to a limited variety 
of assays; redesigning is required for it to cater to other varieties of assays and to 
serve as a generic platform. As a result, microfluidics technology are employed 
mainly in specialized laboratories with the capability to design a suitable microfluidic 
assay platform for a specific assay [33].  
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Table 1.1. Classification of miniaturized assay platforms 
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1.2 Advances in Biologically Relevant Assays for Drug Discovery 
 In the 21st century, there has been a growing trend to move away from 
biochemical-based assays, and to apply cell-based assays for drug discovery [34]. 
Cell-based assays characterize a range of variables such as cell proliferation, toxicity, 
motility, generation of a measurable product, and cell morphology [35–39]. Cell-
 18 
based assays offer a more accurate representation of the real-life model since live 
cells are used, and they offer the possibility of a dynamic experiment through 
monitoring the number and/or the behaviour of live cells [40].  
To ensure compatibility to HTS, many of the cell-based assays developed 
were mostly homogeneous assays [41]. Hence, miniaturization of homogeneous cell-
proliferation and toxicity assays remained popular in 1536-well plates [42]. In these 
assays, the readout (fluorescence, absorbance or luminescence) for each data point is 
the collective effect of the cells in the entire well. Thus, data processing for 
homogeneous assays is convenient and relatively hassle-free. However, the 
“collective readout approach” does not provide details on individual cellular behavior, 
and makes it difficult to assess the accuracy of the data. Hence, there is a shift from 
using homogeneous assays to using heterogeneous assays in drug discovery [43].  
With the advances in molecular labeling technologies, heterogeneous assays 
such as high-content screening (HCS) assays reduce false positives and negatives in 
screenings through systematic build-up of individual cellular details to produce a 
meaningful and representative collective data set [44]. The quality of data can be 
assessed from the fluorescence staining of the tagged proteins within the cells of the 
individual data points, thus allowing the troubleshooting of assays to be conducted in 
a more systematic and productive manner [45]. In addition, the wide range of assays 
targeting different cellular pathways offers flexibility to observe specific molecular 
phenomenon based on the study [46–47]. Overall, HCS cell-based assays allow for a 
more focused compound production and ensure a more meaningful screening outcome 
as compared to standard homogeneous cell-based assays. Insights from these 
information-rich assays could help effective drugs to be discovered more efficiently, 
thus saving considerable time and expenses [41].  
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The shift in the choice of assays from biochemical-based to homogeneous 
cell-based to heterogeneous cell-based assays in drug discovery is motivated by 
improvement in the quality of the screens [38, 41]. Until the 1990s, the aim of HTS 
was to generate as many lead compounds as possible to battle the high elimination 
rate in secondary and subsequent screens. However, in recent years, drug discovery 
no longer involves merely generating numerous lead compounds, rather, it strives to 
improve the quality of the lead compounds generated so that more lead compounds 
would eventually become commercialized drugs. To improve the quality of the lead 
compounds, there has to be a shift towards heterogeneous cell-based assays as they 
not only decrease false positives and false negatives, but also allow for better quality 
assessment of the assays performed [34].  
 
1.3 A Trend Towards Clinically Relevant Cell Sources for Cancer Drug 
Discovery 
         Besides the transition in the choice of assays used for cancer drug discovery, 
the choice of biological samples for drug screening evolved from using kinases to 
cancer cell lines, to primary cells [48]. Pepita et al. demonstrated that primary tumor 
cells are more drug-resistant as compared to cancer cell lines, thus using primary 
tumor cells from human patients for cell-based assays can eliminate false positives in 
the cancer drug screening [49]. Since supplies of primary tumor cells are limited, the 
ability to miniaturize the popular cell-based assays for HTS becomes an attractive 
long-term goal in drug discovery.     
However, from mid 2000’s, the evolving cancer stem cell (CSC) theory has 
brought a new perspective to cancer biology [50]. Although CSCs represent a rare 
subset of cancer cells residing within the tumor, they are capable of escaping 
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chemotherapy and driving tumor growth by metastasis [51]. Hence, the treatment of 
cancer has shifted its focus to target cancer stem cells. Very recently, Grupta et al. 
demonstrated the feasibility to screen against CSCs by developing a cell line that 
retains the drug resistance characteristics of CSCs [52]. However, the ability to probe 
the CSCs in its native form without genetic alteration would ensure the relevance of 
the sample and provide interesting insights to CSC biology.  
Sample limitation seen in primary tumor cells is associated with their lack of 
immortality, i.e. these cells would perish with time [48], whereas sample scarcity of 
CSCs is due to the low prevalence of CSCs in the population of tumor cells [51]. To 
date, assays still lack the ability to process limited and scarce samples such as CSCs.  
With the aid of assay miniaturization, it may be possible to apply standard biological 
techniques like Western blotting to these scarce samples in the future.    
 
1.4 Developing a Niche in Assay Miniaturization 
To develop biologically relevant assays to reduce the dropout rates of the 
screened hits, new miniaturization techniques should allow popular heterogeneous 
assays to be conducted at high throughput to increase efficiency and reduce cost. 
Biological samples such as CSCs that are limited and scarce are not well-suited for 
the existing miniaturization technologies. Although microfluidics platforms maximize 
the number of data points, there is still a minimum quality of cells required to enable 
such experiments. Similarly, cell seeding in microarray platforms are usually not 
selective to the spots whereby the reactions take place, hence resulting in wastage of 
precious cells [28]. The ability to utilize miniaturized assays despite sample scarcity 










Fig. 1.1. The relationship between miniaturization, assays and samples in the 20th and 
21st century. Note: → means ‘developed for’. 
 
The relationship between miniaturization, assays and samples in the late 
1990’s is very much different from today. In the late 1990’s, drug discovery was more 
‘platform-centered’. It was important for samples and assays that were applied for 
HTS to be economical and convenient for assay miniaturization [19]. However, in the 
21st century, samples that are found to be biologically relevant to the disease type are 
usually scarce and limited, hence, it would be important to develop the assay and 
miniaturization platform in a way that would minimize sample usage [34].  
Among the three platforms that were discussed, the microarray technique has 
the best potential to handle scarce biological samples. Conventional microarray falls 
short in handling scarce samples because the assay points are not self-contained after 
repeated rinsing. Hence, we have developed a new microarray technique called 
DropArrayTM to ensure that each assay point is self-contained and free for access 
(dispensing) at any point of the experiment. To ensure convenience of usage, this 
technology is developed to be compatible with common laboratory equipment 
including microscopes, plate readers, robotic dispensers and standard pipettes.  
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In the current landscape, we found most of the miniaturized assay technology 
targets at increased throughput and reduced volume (Fig. 1.2). However, such 
technologies are expensive to adopt, and the sophistication may not be suitable for 
most standard laboratories. Hence, we have focused on creating a miniaturized assay 
technology that caters to the daily use of research laboratories, i.e. lower throughput 
assays at microliter scale.  











Fig. 1.2. Technology landscape of the various miniaturization techniques developed.  
 
1.5 Research Objectives 
In this thesis, the goal is to develop a miniaturization assay platform, 
DropArrayTM, that allows for parallel rinsing on a flat, selectively hydrophilic-
hydrophobic patterned surface. The quality of the patterned surface should be 
maintained to isolate the individual assays throughout the experiment. The approach 
is then optimized for high-content cell-based assays, and the effects on the assay due 
to a reduction in cell number and assay volume are investigated. Lastly, this platform 
is applied toward enriching scarce cancer stem-like cells, and studying their drug 
resistance characteristics.  
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Chapter 2 – Development of the DropArrayTM Technology for Miniaturized 
Cell-Based Assays  
 
2.1 Introduction 
The ability to perform miniaturized heterogeneous assays on a selectively 
hydrophilic-hydrophobic patterned surface is probably one of the most studied 
miniaturization strategies [1–3]. An array of hydrophilic spots is created on the slide 
for a set of assay reactions. Separating the hydrophilic spots is the hydrophobic region 
that serves to prevent cross-contamination between the hydrophilic spots. In the 
platforms that have been developed to run conventional miniaturized assays, the 
rinsing steps and the introduction of reagents are accomplished by a continuous flow-
through approach [4]. This means that all the spots are addressed simultaneously in a 
single flow. Several applications have been demonstrated using this technique to 
perform miniaturized assays, including micro-ELISA, DNA microarray, protein 
arrays and cell arrays [5–7].  
The flow-through approach in microarrays is a lot simpler as compared to that 
of microfluidic chips, whereby a complex network of microchannels is used to deliver 
reagents. Despite its simplicity, there are inherent challenges associated with applying 
the microarray technique to heterogeneous assays. The first challenge is surface 
wetting, whereby the numerous rinsing steps in the flow-through approach may 
deteriorate the integrity of the hydrophobic patterns, resulting in a loss of 
hydrophobicity. As the hydrophobic patterns serve to separate the hydrophilic spots 
where the assay reactions take place, such a loss of hydrophobicity would lead to an 
increased risk of cross-contamination between the hydrophilic spots [8]. Hence, it is 
only at the beginning of the assay, when the hydrophobic pattern is intact, that 
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reagents can be directly dispensed onto the individual spots. In the later part of the 
assay, when the integrity of the hydrophobic pattern has deteriorated, reagents need to 
be introduced in a parallel flow. To overcome the aberrant signals due to cross-
contamination, local reference spots have been introduced to normalize the 
background signals that arise from cross-contamination [9]. Another challenge 
encountered in using the flow-through approach is cell loss. The flow-through rinsing 
approach induces shear stress at the surface, thus affecting cell adhesion during the 
assay. Cheong et al attributed ~ 40% cell loss in applying the continuous flow-
through approach for high-content cell-based assays. Hence, cell loss and surface 
wetting are critical challenges to overcome for the implementation of microarray for 
heterogeneous assays [10]. 
Thus, an ideal fluidics handling technology should present both the ability to 
introduce gentle rinsing procedures to minimize cell loss, as well as the capability to 
protect the integrity of the hydrophobic layer during the assay. Theoretically, this can 
be accomplished using a suitable oil as an interface between the slide and the rinsing 
buffer [11]. Various oils, such as silicone oil, mineral oil and perfluorocarbon liquid, 
have been demonstrated to be particularly useful in insulating droplets in digital 
microfluidics applications [12–13]. However, the fluidics to apply oil that selectively 
protects the hydrophobic layer but not the hydrophilic spots will likely be complicated.  
This chapter explored the feasibility of using various types of oils to insulate 
the hydrophobic layer and prevent surface wetting [14]. It examined the interactions 
of oil with the array of aqueous drops, and the selectively hydrophilic-hydrophobic 
patterned slide during parallel rinsing [14]. A novel technology termed the 
DropArrayTM was introduced to enable parallel rinsing on a selectively hydrophilic-
hydrophobic patterned slide without wetting the hydrophobic layer [14]. This 
  30 
platform was applied to a generic cell-based assay, and its performance was compared 
with that of 96-well plates [15]. The DropArrayTM technology presents an attractive 
platform that allows for convenient miniaturization of heterogeneous assays that are 
conventionally performed in multi-well plates, thus opening a myriad of opportunities 
to miniaturize heterogeneous assays such as ELISA and high-content screening cell-
based assays. 
 
2.2 Experimental Methods 
2.2.1 Materials 
The gastric cancer cell line, MKN7, was obtained from American Type 
Culture Collection (ATCC) (Manassas, MA, USA), and cultured in the recommended 
medium containing 1% penicillin/streptomycin and 10% of heat-inactivated fetal 
bovine serum (FBS) (Invitrogen-Life Technologies, Carlsbad, CA, USA). Silicone oil 
(Catalog #378348, 20 cSt) and mineral oil were obtained from Sigma Aldrich (St. 
Louis, MO, USA), while perfluorocarbon liquid (PFCL) was obtained from 3M 
(Catalog #FC3283, St. Paul, MN, USA). Fluorescein 5-isothiocyanate and 
tetramethylrhodamine (TAMRA) dyes used for rinsing experiments were obtained 
from Sigma Aldrich (St. Louis, MO, USA). The poly(tetrafluoroethylene) (PTFE)-
printed slides were purchased from Thermo Scientific (Waltham, MA, USA). The 
AlamarBlue® cell proliferation kit was purchased from Invitrogen-Life Technologies 
(Carlsbad, CA, USA).  
 
2.2.2 Optimization of Rinsing Buffer Left-Over Volume to Draining Angle  
2 ml of Dubelcco’s Mininum Eagle Medium (DMEM), containing 10% FBS, 
was dispensed into each of the spots on the PTFE-printed slide, and the entire slide 
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was immersed in 15 ml of PFCL in a Petri dish. The PFCL was then drained and 
introduced into a beaker of rinsing buffer (phosphate buffered saline (PBS)) at various 
angles. The slide was removed at the same angle and stored in PFCL to prevent 
evaporation. Subsequently, 2 ml of TAMRA solution (1 mM) was added into each spot 
of the rinsed slide, and the leftover volume was estimated by reading the relative 
fluorescence intensity using a confocal microscope (Insight, Evotec Technologies, 
Germany), with reference to a freshly dispensed TAMRA solution (2 ml). Results 
were taken as an average from 10 representative locations on the PTFE-printed slide.  
 
2.2.3 Cross-Contamination Study Using Rinsing Station  
The cross-contamination test was conducted in a reverse approach to that 
described in Section 2.2.2. 2 ml of Fluorescein solution (1 mM) was first dispensed 
onto the spots. This was followed by rinsing using the Rinsing Station. Subsequently, 
2 ml of PBS was dispensed onto the spots. The dilution effect was estimated by 
detecting the fluorescence intensity using the IX61 fluorescent microscope (Olympus, 
PA, USA). Another test involved using the PTFE-printed slide with an array of 224 
spots (diameter = 600 mm). 100 nL of TAMRA solution (5 nM) in PBS was dispensed 
onto the spots in the array using the BioDot dispenser (Irvine, CA, USA), and imaged 
under IX61 microscope. Subsequently, the slide was rinsed using the Rinsing Station, 
and imaged for wetting and residual TAMRA solution on the slide. 100 nL of 
Fluorescein (100 nM) in 1×PBS was then dispensed onto each spot to produce an 
array of green fluorescent drops, and the slide was then inspected to verify if the 
hydrophilic-hydrophobic nature was retained. 
 
  32 
2.2.4 Development of the Alpha Prototype DropArrayTM Accelerator and Plates 
The alpha prototype DropArrayTM Accelerator was contracted to Akribis 
Systems Pte Ltd for development based on our specifications [14]. As for the 
DropArrayTM plates, standard PTFE slides were adhered to custom-designed slide 
holders. 
 
2.2.5 AlamarBlue® Assay in DropArrayTM Plate Versus 96-Well Plates 
It was necessary to optimize the assays conducted on DropArrayTM because of 
the difference in assay volume and cell culture surface area as compared to the 96-
well plate. The surface area on each spot on a DropArrayTM plate (3.14 mm2) was 
approximately one-tenth that of a 96-well plate (31 mm2). Hence, 7,500 cells and 750 
cells were used for each well of the 96-well plate and for each spot on the 
DropArrayTM plate, respectively. 
To account for the difference in assay volume on the DropArrayTM and 96-
well plate, the AlamarBlue® assay was preformed with slight modifications to the 
standard protocol. Instead of the direct addition of 10 ml of AlamarBlue® to each well 
containing 100 ml of media in the 96-well plate, we premixed the AlamarBlue® media 
cocktail at the same ratios, and performed an aspiration step before adding 100 ml of 
the cocktail to each well in the 96-well plate. The DropArrayTM plate was washed 
using the DropArrayTM Accelerator before 2 ml of the cocktail was added to each of 
its spot. To avoid saturation of signal due to miniaturization on the DropArrayTM plate, 
the incubation time for the AlamarBlue® assay was shortened to 1 h. For the 96-well 
plate, we adhered to the 3-h incubation period as recommended by the standard 
protocol. The fluorescent signal from each spot was subtracted from its background, 
and normalized against its own spot to reduce the coefficient of variation in the data. 
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The results were obtained from an average of 10 spots from representative locations 
on the DropArrayTM plate, and 4 wells from the 96-well plate. 
 
2.3 Results and Discussion 
2.3.1 Miniaturization on PTFE-Printed Slide Versus Conventional Well Plates 
Experiments were conducted with commercially available slides with PTFE-
printed surfaces [15]. The printing created artificial hydrophilic spots on a flat glass 
slide by selective hydrophilic-hydrophobic patterning. Each spot was 2 mm in 
diameter and could carry a volume of 1–4 ml. In this array of 48 spots, the pitch 
between spots was 4.5 mm, similar to that of standard 384-well plates. However, the 
scale of miniaturization was similar to that of a 1,536-well plate, whereby each 
individual well has the capacity to hold 6–10 ml. 
 Although the volumes in 1,536-well plates and the PTFE-printed slides were 
on the same order, it was difficult to aspirate and dispense into the wells of the 1,536-
well plates. Sophisticated liquid handling capabilities were required, rendering it 
impossible for most skilled biologists to conduct such a scale of miniaturization in the 
laboratories. Interestingly, the spots on the PTFE-printed slides, which held less 
volume as compared to wells on the 1,536-well plates, were visually simpler to 
facilitate dispensing; dispensing could be easily accomplished using the standard 10-
ml laboratory pipettes. The advantage observed with flat PTFE-printed slides was 
attributed to the “wall-less” nature of the slides, causing the droplets to have less 
volume in contact with surfaces, thus making the droplet more accessible for 
aspiration [16]. Using the PTFE-printed slides, 2-ml assays could be conveniently 
conducted through this novel platform.     
 









Fig. 2.1. Photographs of commercially available 1,536-well plate and our PTFE-
printed slide. 
 
2.3.2 Protection of PTFE-Printed Surface from Surface Wetting 
 In the development of a parallel-rinsing technique on a flat selectively 
hydrophilic-hydrophobic patterned slide, we observed that the quality of the 
hydrophobic layer was critical for conducting repeated rinsing. Based on our 
experience in developing and testing the selectively hydrophilic-hydrophobic cell 
microarray [17], we concluded that a monolayer hydrophobic coating of 
heptadecafluoro-1,1-2,2-tetrahydrodecyl triethoxysilane (FTES) via vapor-phase 
deposition could not withstand the rigorous rinsing conditions. After 3–5 rounds of 
repeated rinsing, the FTES layer would start to peel off from the glass slide. A thick 
hydrophobic PTFE layer was required to withstand such rigorous rinsing steps.  
A thick PTFE layer was able to maintain its hydrophobicity most of the time. 
Surface wetting would occur only when the surface was exposed to 50% FBS in PBS 
and ethanol. When the PTFE layer came in contact with the 50% FBS solution, the 
surface wet irreversibly, and was not able to restore its hydrophobic nature due to the 
solution’s viscosity and stickiness. Similarly, when a liquid of low surface tension, e.g. 
ethanol (21.55 mN·m–1), was dispensed onto the hydrophilic spots of the PTFE-printed 
slide, the liquid spread to wet the PTFE layer quickly. The hydrophobicity of the 
 
1,536 well-plate  48 spots on flat PTFE-printed slide 
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PTFE layer could rarely be restored in such circumstances, especially when multiple 
reagents with properties similar to FBS and ethanol have to be used during an assay. It 
was, therefore, important to find a suitable oil that would be capable of protecting the 
PTFE-printed layer, and preventing wetting at all times since surface wetting would 
usually be irreversible. 
 
2.3.2.1 Application of Oil for Protecting PTFE Surface 
 Various synthetic oils such as silicone oil, mineral oil and perfluorocarbon 
liquid have been used in miniaturization technologies [18–20]. In digital microfluidic 
applications, Srinivasan et al. had demonstrated their ability to deliver droplets in 
series within microchannels whereby silicone oil was applied to prevent the droplets 
from interacting. In addition, Cho et al. have developed a microfluidic technology 
primarily using a proprietary oil mixture to create water-in-oil emulsions to generate, 
load and merge droplets even down to the picoliter range [20]. In these examples, the 
success of implementing novel microfluidic capabilities was attributed to the ability to 
apply suitable oils for specific applications.  
Herein the performance of the synthetic oils was compared based on the ease 
of draining the oil, the ability for the drops to ‘pop out’ and disperse into the rinsing 
buffer, the wetting of PTFE surface during rinsing, and the ease of dispensing drops 
(see Table 2.1).  
It was noted that only PFCL, and not silicone and mineral oil, was suitable for 
use in the rinsing process. This was likely due to the low viscosity and surface tension 
of PFCL, which allowed for the quick draining of oil, leaving behind a thin protective 
layer of oil on the drops and the PTFE surface. This thin layer of oil quickly dispersed 
to allow the rinsing buffer to interact with the drops, while protecting the PTFE 






surface from wetting. It also allowed for convenient dispensing through the oil layer; 
in contrast, dispensing droplets was difficult when mineral or silicone oil was used. 
Throughout the entire process, the PTFE surface remained hydrophobic because of 
the protective function of the PFCL layer. It was also observed that although silicone 
oil seemed suitable for preventing surface wetting, its high viscosity resulted in slow 
‘popping’ of droplets (i.e. the droplets took a longer time to be rinsed off and drained), 
and an increased difficulty in dispensing new droplets.  
Table 2.1. Summary of the fluidics test to study the ease of draining of oil, ‘popping’ 
of aqueous drops through the oil layer, wetting of hydrophobic layer, and dispensing 
aqueous reagent through the oil layer.  
‘Popping’  Draining 
50% FBS Ethanol 
Wetting Dispensing 
Mineral Oil Very Slow Cannot Cannot Visible Difficult 
Silicone Oil Slow Easy Slow No Possible 
PFCL Quick Easy Easy No Easy 
 
2.3.2.2 DropArrayTM Technology – A Parallel Rinsing Approach for Teflon-Printed 
Flat Glass Slides 
During rinsing, the rinsing buffer was brought into the rinsing chambers on the 
plate to ensure adequate mixing of aqueous drops with the rinsing buffer, as well as to 
ensure that the unbound antibody was washed off to reduce non-specific binding [21]. 
In microfluidic platforms, microchannels and microarray technologies, the flow-
through approach to introduce rinsing buffers has probably been the most widely 
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applied technique [22]. This ensured a consistent and laminar flow of rinsing buffers 
to produce uniform and reproducible washing. However, this approach was not 
feasible in the implementation of our parallel rinsing technology. The PTFE slide 
used in our application was ~ 1 inch wide, as opposed to the microfluidics channel 
that has a diameter of hundreds of microns. When the diameter was small, as in the 
microfluidics channel, it would be easy to maintain laminar flow, but for our PTFE 
slide, the speed profile gradient of the rinsing buffer would be huge across the flow, 
resulting in non-uniform washing of the spots [23]. Also, the shear force of the flow 
would likely weaken cell adhesion, resulting in substantial loss of cells in our 
application. Such a loss of cells has been reported by Cheong et al. [10]. 
Inspired by the standard protocol in Western blotting whereby blots are left on 
a shaker to ensure uniform rinsing, we adopted the shaking process and noted a 
dramatic improvement in the quality of the rinse. By introducing a bulk quantity of 
rinsing buffer into the rinsing chamber, and later allowing the rinsing chamber to 
shake, uniform mixing between the drops and the rinsing buffer was achieved. This 
would be illustrated and characterized throughout the chapters.  
To apply this unconventional rinsing approach to miniaturized assay 
technology, we devised a unique sequence of actions for rinsing on the DropArrayTM 
platform [14]. To enable rinsing, the PFCL covering the drops was first drained, and 
the rinsing buffer was subsequently introduced (Fig. 2.2a). By adjusting the shaking 
based on the requirement of the assay, uniform mixing of the drop with the rinsing 
buffer was ensured. For cell-based assays, the shaking process should be gentle to 
minimize any unintentional cell detachment (Fig. 2.2b). At the end of the rinsing 
process, the slide should be immersed in PFCL once again so that PFCL could replace 
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the rinsing buffer to allow new drops to be dispensed readily onto the hydrophilic 
spots (Fig. 2.2c).   
We envisioned that users of the DropArrayTM technology would only be 
required to dispense (Step 3) onto the individual spots of the slide (see Fig. 2.2). 
Rinsing and draining (Steps 1 and 2) would be taken care of by the specialized 





   
 
 
Fig. 2.2. Schematic of the selectively hydrophobic-hydrophilic patterned slide 
undergoing rinsing.  
 
2.3.3 Optimization of Protocols for DropArrayTM Technology 
For the DropArrayTM technology to be applied towards various heterogeneous 
assays, we must ensure the uniformity of residual volumes and minimum cross-
contamination between spots. These critical factors were investigated to illustrate the 
feasibility of the DropArrayTM technology. 
 
2.3.3.1 Effect of Draining Angle on the Uniformity of Residual Drops After Rinsing 
 The rinsing buffer needs to be drained before the addition of PFCL to protect 
the residual volume (see Fig. 2.2). We found that the angle at which the PTFE-
patterned slide exited from the rinsing solution was important to the volume and the 
Rinsing Buffer 
 (2) Draining 
PFCL (1) Rinsing 
Before Rinsing After Rinsing 
Shaking (a) (b) 
(3) Dispensing 
(c) (d) 
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uniformity of the leftover drops. By systematically adjusting the exit angle in the 
draining step (see Fig. 2.3), we could estimate the residual volume based on the 
addition of 2 ml of TAMRA solution (Vref = 2 ml) to a rinsed slide, and measure the 
fluorescence with respect to a reference drop (Fig. 2.4). The residual volume, Vresidual, 




















Fig. 2.3. Schematic of PTFE-printed slide exiting from the rinsing buffer. 
 
We observed that the PTFE-printed slide exiting from the reverse angle 
yielded the best performance. The reverse angle was defined as -45°, with the droplets 
facing downwards (Fig. 2.3). Approximately 100 nl of rinsing buffer remained on the 
hydrophilic spots after rinsing and draining. This was the minimum residual rinsing 
volume achievable, and was obtained at an exit angle of -45°. The residual volume 
was found to be very consistent, and therefore this draining protocol was implemented 
in the DropArrayTM Accelerator.   
-45° +45° Slide exits from 
reverse angle 









Fig. 2.4. Fluorescence intensity due to dilution by residual drop and reference at 
different exit angles. 
 
2.3.3.2 Overcoming Cross-Contamination in DropArrayTM Technology 
Cross-contamination between spots is probably the most challenging task to 
overcome in any microarray platform [24]. We highlighted the application of using 
reference spots to compensate for the signal due to cross-contamination in DNA 
microarray chips. However, to develop a platform similar to the 96-well plates, the 
microarray needs to be free from cross-contamination between spots, as well as 
internal cross-contamination that arise from residual reagents present even after 
rinsing. Herein we considered both sources of cross-contamination in developing the 
DropArrayTM technology [14]. 
Internal cross-contamination is due to insufficient dilution within a well. After 
the aspiration step in 96-well plates, there would be a 5% reagent leftover for each 
well, hence, the effective dilution was only ~ 20× during rinsing. To increase the 
dilution effect, the well would need to be rinsed ~ 2–3 times to minimize the effects 
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In the DropArrayTM plate, the rinsing buffer (45 ml) was mixed thoroughly 
with the reagents during the shaking. Hence, the dilution effect in the spots of a 
DropArrayTM plate depended on the number of spots with high concentrations. If all 
48 spots were dispensed with solutions of high concentration, and were subsequently 
rinsed using the DropArrayTM approach, the dilution effect would be calculated to be 
~ 450×, which was ~ 22 times more effective than a single rinse on well plates. We 
experimentally estimated the dilution factor by dispensing 2-ml drops of TAMRA 
solution to the spots of the PTFE slide, rinsed using the set-up in Fig. 2.5, and 
compared the fluorescence intensity of the drops before and after rinsing. The dilution, 
however, was determined to be ~ 200× after washing, which was lower than the 
postulated value of 450×. This was likely due to the non-specific binding of TAMRA 
solution to the glass surface. Reduction of this non-specific binding could be achieved 










Fig. 2.5. Early developments of the rinsing station to study parallel rinsing on the 
DropArrayTM.   
 
While developing the DropArrayTM technology, we postulated that the 
proximity of the spots would cause cross-contamination and irreversible wetting as 
the drops might interact with each other while mixing with the rinsing buffer. To 
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study the efficacy of our rinsing approach, we used slides with a spot-to-spot pitch of 
2.25 mm and a spot diameter of 600 mm. Thus, the proximity of the drops was ~ 1.65 
mm. We dispensed 100 nl of TAMRA solution on the slide, rinsed the slide using the 
set-up in Fig. 2.5, and then dispensed 100 nl of Fluorescein on the same spots. It was 
interesting to observe that the Fluorescein drops remained spherical on the spots, 
suggesting that the PTFE layer maintained its hydrophobicity. Furthermore, negligible 
contamination from TAMRA solution was observed (Fig. 2.6b), indicating negligible 







Fig. 2.6. Investigation of cross-contamination in a densely packed array of drops. 
Micrographs of the PTFE-printed slide after (a) TAMRA solution was dispensed onto 
the spots, (b) the slide was subjected to rinsing, and (c) Fluorescein solution was 
dispensed onto the spots. Scale bar = 500 mm.    
 
2.3.4 Development of the DropArrayTM Accelerator and DropArrayTM Plate 
To remove the variability between experiments performed by hand and the 
early rinsing machine, we greatly improved the robustness of parallel rinsing by 
developing the DropArrayTM Accelerator alpha prototype [14]. The latter could be 
programmed to alter the volume of the rinsing solution, the speed of entry of the 
rinsing solution, the shaking speed, the draining angle and the draining duration. The 
c a b 
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Fig. 2.7. Alpha prototype of DropArrayTM plate and DropArrayTM Accelerator with 
user interface to input fluidics parameters.   
 
With the knowledge from earlier experiments, we programmed the 
DropArrayTM Accelerator to undergo a sequence of actions to interface with the 
operator in order to (1) load the DropArrayTM plate, (2) enclose the rinsing chamber, 
(3) drain the PFCL and introduce the rinsing buffer, (4) shake the rinsing chamber, 
and subsequently reverse the order of operation to drain the rinsing buffer and return 
to its original position. PFCL was then manually added to prevent evaporation of the 
residual rinsing buffer in the individual hydrophilic spots before further dispensing 
the next reagent (Fig. 2.8).  
DropArrayTM plate Alpha Prototype of DropArrayTM Accelerator 
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Fig. 2.8. Steps programmed on the DropArrayTM Accelerator to perform parallel 
rinsing on the DropArrayTM plate. 
 
2.3.5 Adaptation of DropArrayTM Technology to Homogeneous Cell-Based Assays 
Homogeneous cell-based assays are probably the most popular assays for drug 
screening and research [25]. The common homogeneous cell-based assays include the 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, the MTS 
tetrazolium assay, the AlamarBlue® assay and the Promega series of screening assays, 
including Caspase 3 and 7 assays [26–29]. The AlamarBlue® assay is a popular cell 
proliferation assay because of its good linearity in fluorescence signal with respect to 
the number of cells [30]. Also, the reagent is non-toxic to cells [31], which means that 
one can conveniently conduct time course experiments to study the effects of 
stimulants on cells [14]. Herein the DropArrayTM technology was optimized to be 
compatible with the AlamarBlue® assay [14].  
We studied cell growth on the DropArrayTM plate as compared to 96-well 
plate for a 4-day period by applying the AlamarBlue® assay on the gastric cancer cell 
line, MKN7. Unlike the 3-h incubation period for the 96-well plates during the assay, 
Steps in order of 
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an incubation period of 1 h was applied to DropArrayTM to avoid signal saturation. 
Thus, DropArrayTM enabled the shortening of assay time by 67%. 
To enable the DropArrayTM plate to be read on standard plate readers, there 
were several challenges to overcome. We had to specially design an adaptor for the 
DropArrayTM plate to match the 384-well plate footprint in order to be compatible 
with the standard plate reader [14]. The field of detection of the objective in the Tecan 
Safire 2 is 2 mm in diameter [32]. For homogeneous assays conducted in standard 
384-well plates (well diameter = 2.7–3.5 mm), reading at any part of the well would 
yield a similar result. However, reading the DropArrayTM plate using standard plate 
readers could be tricky. Since the 2-ml drops on the DropArrayTM plates were 
spherical, it was important to read the entire drop. Any offset between the objective 
and the DropArrayTM plate would result in not only a loss of signal, but also 
inconsistent results, should multiple readings be taken at different time points for the 
same drop (see Fig. 2.9). Thus, the plate adaptor was changed to aluminum so as to fit 
the DropArrayTM plate better and produce a consistent readout from the Tecan Safire 
2. In addition, the objective of the plate reader was adjusted to the center of the well 
of the DropArrayTM plate. This would optimize the scan by adjusting the objective 
with respect to the reference well. Hence, the DropArrayTM plates were designed to be 
compatible for use with the commercial plate readers. 
In view of the AlamarBlue® assay results (Fig. 2.10), it was interesting to note 
that initial growth of MKN7 cells on DropArrayTM plate was slightly more efficient as 
compared to 96-well plates. In fact, similar observations of slightly increased initial 
proliferation on DropArrayTM plate as compared to 96-well plates were noted for other 
cell lines, including hepatoma carcinoma HepG2, mouse fibroblast NIH3T3, breast 
adenocarcinoma MCF7. This was likely due to the faster settling of cells in 2-ml 
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assays and the suitability of our technique to prepare the slides for cell culture. 
Usually cells would settle on the DropArrayTM slide, and start to adhere within 2–4 h 
of cell seeding, but the process would take ~ 6–10 h in 96-well plates. Thus, the 





   
 
 
Fig. 2.9. (a) DropArrayTM plate aligned to the objective of the plate reader to produce 
maximum signal readout. (b) Off-aligned DropArrayTM plate would result in 









Fig. 2.10. Normalized MKN7 cell growth rate in (p) 2-ml DropArrayTM and (g) 100-
ml 96-well plate AlamarBlue® assays. Seeding concentrations of 750 and 7,500 cells 
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It was also observed that the proliferation rate of MKN7 cells on the 96-well 
plate appeared to be exponential, whereas that on the DropArrayTM plate was rather 
linear. According to Hojo et al., the doubling time of MKN7 cells was reported to be 
~ 66 h [33], which was confirmed with our findings for the 96-well plate. Thus, there 
appeared to be issues in the long-term culture of cells on the DropArrayTM plate. 
Upon examining the wells of the DropArrayTM plate, we did not observe cell 
detachment from the glass surface, suggesting that the change in growth profile was 
not a result of rinsing on the DropArrayTM Accelerator.   
The linearity in cell proliferation rate observed on the DropArrayTM plate was 
postulated to be due to insufficient nutrients for cells in the 2-ml drop. The scale of 
miniaturization on the DropArrayTM plate as compared to 96-well plates was 50× in 
volume, but only 10× in surface area. To ensure a comparable cell confluency as for 
the 96-well plate, we seeded only 750 cells in the spots of the DropArrayTM plate. 
This meant that the media-to-cells ratio was 5× less as compared to that in the 96-well 
plate. To verify our hypothesis, we reduced the number of MKN7 cells cultured on 
DropArrayTM plate to 200 so that the media-to-cells ratio was comparable to that for 
the 96-well plate. In this case, an exponential growth of MKN7 cells was observed 
after 4 days of culture. This study illustrated that it would be important to thoughtfully 
adapt cell-based assays when using the DropArrayTM technology, as the cell saturation 
in the spots of DropArrayTM would likely alter their growth characteristics.  
 
2.4 Summary 
Although microarray technologies have been widely applied to ELISA, protein 
arrays, cell-based assays and DNA detection, there remain several challenges 
associated with performing miniaturized heterogeneous assays on a selectively 
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hydrophilic-hydrophobic patterned surface. Irreversible wetting of the hydrophobic 
surface and non-uniformity in signal across the array are among the most challenging 
problems in every microarray platform. This chapter described the use of PFCL to 
selectively protect the hydrophobic surface throughout the assay, while allowing 
access to the array of hydrophilic spots without cross-contamination. The interfacial 
characteristics between the drops and PFCL rinsing buffer and the PFCL-hydrophobic 
surface interactions have been examined. DropArrayTM technology was established to 
allow for parallel rinsing on a flat, selectively hydrophilic-hydrophobic patterned 
surface. To ensure the reproducibility of the parallel rinsing experiments, the 
DropArrayTM Accelerator and the DropArrayTM plates were developed. The 
DropArrayTM platform was also optimized to ensure compatibility with standard plate 
readers. To illustrate the potential applications of this technology, we adapted the 
AlamarBlue® assay to study cell growth characteristics in miniaturized assays using 
the DropArrayTM platform. The DropArrayTM plates would also allow for coatings and 
surface functionalization chemistries to be implemented [34] for stem cell [35], neural 
cell [36] and other primary cell cultures [37]. 
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Chapter 3 – Optimization of DropArrayTM Parallel Rinsing Technology for 
High-Content Cell-Based Assays 
 
3.1 Introduction 
Over the last decade, imaging as a detection mode for cell-based assays has 
opened many opportunities to measure phenotypic endpoints of interesting biological 
phenomena, ranging from cell differentiation to compound pharmacology and toxicity 
[1]. With increased applications for high-content screening (HCS) in scientific 
research, miniaturization of HCS assays has become an attractive solution to reduce 
cost and increase efficiency in data collection and management [2].  
However, developing miniaturized assay technologies for HCS can be 
challenging. HCS assays require multiple washing steps using various reagents for 
fixation, permeabilization, blocking and antibodies staining; therefore, demanding and 
stringent liquid handling and fluidics capabilities are needed in the successful 
miniaturization of HCS assays [3–5]. Schaack et al. developed the DropChip for 
conducting both transfection and reverse transfection assays on a flat, selectively 
hydrophobic-hydrophilic patterned slide [6]. Like many microarray technologies, the 
DropChip could not prevent wetting of the hydrophobic layer once the parallel flow 
was introduced. Hence, elaborate cooling module was utilized to maintain the 
atmosphere at dew point. This prevented the evaporation of drops, and also ensured 
the quality of the patterned surface in the early part of the HCS assay. However, this 
miniaturization approach lacked flexibility in liquid handling and was not easily 
amenable for scale-up. 
To accommodate the liquid handling requirements in HCS assays, 
microfluidic systems might provide a more practical solution. Ye et al. developed an 
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integrated microfluidic system for the complex liquid handling requirements of HCS 
assays [3]. This enabled the study of the mitochondrial membrane potential (MMP) in 
hepatoma carcinoma HepG2 cells upon treatment with various compounds. However, 
the continuous flow-through liquid handling capability applied in microfluidic 
platforms might result in cell loss after multiple rinsing steps. Cheong et al. reported ~ 
40% cell loss at the end of the HCS assays in an integrated microfluidic chip [7].  
In addition, integrated microfluidic chips and microarrays usually lack the 
flexibility to adapt to the variations in HCS protocols other than the designated assays. 
For example, the extracellular signal-regulated kinase (ERK) translocation HCS assay 
involves additional reagents and rinsing steps to improve the uniformity of the 
fluorescence signal within the cells [8]; the multiparameter HCS kits allow for the 
multiplexing of 3 HCS assays to elicit a variant of cellular behavior in a single 
experiment at the expense of additional blocking and rinsing steps [9]. Thus, it is 
difficult to design microfluidic chip that can cater to the diverse range of HCS assays. 
In addition, many miniaturized assay technologies have to establish their own imaging 
capabilities because of their incompatibility with standard HCS imagers [3–6]. 
Judging from the amount technical expertise required to optimize these miniaturized 
assay platforms for HCS assays, and also the need to reinvent capabilities that are 
beyond those available in standard HCS systems, it is difficult to justify the switch to 
miniaturized HCS assays in common biology laboratories.    
The DropArrayTM technology, however, has been designed to overcome the 
disadvantages in conventional miniaturized assay technologies. In this Chapter, 
parallel rinsing on the DropArrayTM Accelerator was optimized to accommodate HCS 
assays [10]. In addition, strategies were developed to ensure compatibility of the 
DropArrayTM plate to the standard HCS imaging platform [10]. Two HCS assays were 
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examined to illustrate the assay kinetics and data compatibility in the miniaturized 
platform [10]. The importance to conduct HCS assays without interference from the 
compound was demonstrated [10]. Specifically, the 2-ml Caspase 3 HCS assay was 
developed to elicit the dose response of doxorubicin, while avoiding the 
autofluorescence from the compound.  
 
3.2 Experimental Methods 
3.2.1 Materials 
Various cancer cell lines including those of liver (HuH7 and HepG2) and 
gastric (MKN7) were obtained from American Type Culture Collection (ATCC) 
(Manassas, MA, USA), and cultured in the recommended medium containing 1% 
penicillin/streptomycin and 10% of heat-inactivated fetal bovine serum (FBS) 
(Invitrogen-Life Technologies, Carlsbad, CA, USA). The HepG2-GFP cell line was a 
gift from Dr. Kwong Joo Leck. Mitotic index and ERK translocation HCS assay kits 
were purchased from Thermo Scientific Cellomics (Pittsburgh, PA, USA). 
Horseradish peroxidase-conjugated secondary antibody was purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA), and ECL chemiluminescence reagents 
were purchased from GE Healthcare Life Sciences (Piscataway, NJ, USA). Caspase 3 
assay for HCS was developed in-house using the following reagents: phosphate 
buffered saline (PBS), 37% formaldehyde solution, Triton-X 100 and bovine serum 
albumin (BSA) (all from Sigma Aldrich, St. Louis, MO, USA), antibody against 
Caspase 3 (BD Bioscience, San Jose, CA, USA and Cell Signaling Technology, 
Beverly, MA, USA), and goat-anti-rabbit IgG Alexa Fluor 647 (Invitrogen-Life 
Technologies, Carlsbad, CA, USA). 
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3.2.2 Miniaturization of HCS Assays Using the DropArrayTM Technology 
The DropArrayTM technology allowed for convenient miniaturization of HCS 
assays based on 2 guidelines. First and foremost, it should be noted that the surface 
area of each spot on a DropArrayTM plate (3.14 mm2) was approximately one-tenth 
that of a 96-well plate (31 mm2). To achieve the same confluency of cells on 
DropArrayTM plates, one-tenth the cell number required for a well in 96-well plates 
was seeded for each spot on the DropArrayTM plates.  
In addition, HCS assays were usually conducted at a fixed volume of 2 ml per 
spot on the DropArrayTM plates. Unlike 96-well plates whereby protocols allowed for 
the addition and partial removal of reagents for each well, DropArrayTM plates 
provided for the washing and replacement with a new drop for each spot. 
 
3.2.3 Fluorescence Spectra Analysis 
The fluorescence spectrum of doxorubicin was analyzed by the FluoroLog 
Spectrophotometer (HORIBA Jobin Yvon Inc., Edison, NJ, USA) at excitation 
wavelengths of 340 nm, 440 nm and 540 nm. Since the peaks of fluorescence 
spectrum at all excitation wavelengths were the same, only the spectrum obtained at 
an excitation wavelength of 340 nm was presented. For analysis of the PTFE surface 
on DropArrayTM plate, Tecan Safire 2 plate reader (Tecan, San Jose, CA, USA) was 
used for reading the ﬂuorescence output signal from 280–750 nm at an excitation 
wavelength of 240 nm. The fluorescence spectrum was verified by reading the 
ﬂuorescence output signal of doxorubicin using the plate reader, which was identical 
to that produced by the spectrophotometer. 
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3.2.4 SDS-PAGE and Western Blot  
50 µg of total protein was extracted from HuH7 cells, boiled at 70°C for 5 min, 
and resolved in a 4–12% SDS-PAGE gel before being transferred onto a 
nitrocellulose membrane. Subsequently, antibody against Caspase 3 was used at 
1:1000 dilution. The target bands were detected by horseradish peroxidase-conjugated 
secondary antibody. Protein bands were recorded on X-ray film by reacting with ECL 
chemiluminescence reagents.  
 
3.2.5 2-ml High-Content Caspase 3 Assay on DropArrayTM 
500 HuH7 cells per spot on the DropArrayTM plate were treated with 
doxorubicin for 18 h. The cells were then fixed in pre-warmed 3.7% formaldehyde for 
15 min, and 0.1% Triton X-100 permeabilization buffer for 10 min. Subsequently, the 
cells were subjected to blocking with 3% BSA in PBS for 30 min before undergoing 
overnight primary antibody staining (1.2 ml of Capase 3 antibodies to 500 ml of 
blocking buffer). Subsequently, secondary antibody staining (2.5 ml of Alexa Fluor® 
647 and Hoechst to 500 ml of blocking buffer) was conducted for 1 h. At the end of 
the assay, the DropArrayTM plate was washed twice in wash buffer II (0.1% Tween in 
PBS), and imaged with Cellomics ArrayScanTM (Thermo Scientific, Pittsburgh, PA, 
USA). 
 
3.3 Results and Discussion 
3.3.1 Optimization of Parallel Rinsing Protocol on DropArrayTM Accelerator for 
HCS Assays 
During the rinsing process with the DropArrayTM Accelerator, the rinsing 
buffer flowed into the rinsing chamber to interact with the array of drops on the 
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DropArrayTM plate. However, a layer of PFCL between the rinsing buffer and the 
drops prevented their interaction and proper rinsing. This could be prevented by 
introducing a waiting period to allow the drops to ‘pop’ into the bulk rinsing buffer. 
Once the drops could interact with the bulk rinsing buffer, the plate was subjected to 
mild shaking to ensure proper mixing between the drops and the rinsing buffer. 
Herein the time required for the drops to ‘pop’ was characterized, and the effects of 
rinsing on cell detachment were examined. The ‘shaking’ period was also optimized 
to ensure sufficient mixing to maximize the fluorescence intensity difference between 
the treated system and its negative control in a HCS assay. 
 
3.3.1.1 Effects of the Various Types of HCS Reagent on the Duration Required for the 
2-ml Reagent Drops to Interact with the Rinsing Buffer  
The interaction of the 2-ml reagent drop with the rinsing buffer at the interface 
was described as ‘popping’. This was an important step to enable parallel rinsing on a 
flat, selectively patterned hydrophilic-hydrophobic slide in Section 2.3.2.1. It was 
particularly important in HCS assays whereby a variety of different reagents of 
different physical properties (including surface tension and hydrophobicity) was used 
during the assay. Hence, we examined the ‘popping’ time required for the various 
types of drops to interact with the rinsing buffer once the DropArrayTM plate was 
rotated back to the rest position (as described in Fig. 2.8.2). 
Drops consisting of 3.7% formaldehyde in PBS required less than 3 sec of 
‘popping’ time to interact with the rinsing buffer. The ‘popping’ time was less than 5 
sec for serum-containing reagents, including blocking buffer, primary and secondary 
antibody solutions. However, when rinsing an array of 2-ml permeabilization buffer 
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consisting of 0.1% Triton X-100, the ‘popping’ time varied substantially, but was 
consistently less than 8 sec.  
The difference in the ‘popping’ time could be due to the difference in surface 
tension between the drops and the rinsing buffer (PBS). The similarity in surface 
tension between the drops and the rinsing buffer would reduce the time required for 
the interfacial interaction. PBS has a surface tension of ~ 70–72 mN/m [11], similar to 
3.7% formaldehyde in PBS [12]. Therefore, these two reagents were observed to 
interact very quickly with the rinsing buffer. In contrast, 0.1% Triton X-100 (16–22 
mN/m [13]) and blocking buffer (3% serum in PBS, ~ 52 mN/m [14], which were 
most different in surface tension from the rinsing buffer (PBS), interacted most slowly 
with the rinsing buffer among the various types of reagents. 
During the implementation of the DropArrayTM Accelerator for HCS assays, 
we fixed the waiting time to 10 sec to ensure complete ‘popping’ of all the drops. For 
assays such as ELISA, the ‘popping’ times were also characterized based on the 
choice of rinsing buffer and the reagents used for the assay.  
 
3.3.1.2 Effects of Cell Loss Upon Multiple Rinsing Required of the HCS Protocol  
In HCS assays, interchange of reagents is accomplished by the multiple 
rinsing steps throughout the assay. However, rinsing steps are likely to contribute to 
unintentional cell loss in the experiment. Cheong et al. reported 40% cell loss 
associated with the continuous flow technique applied to its microfluidics platform [7]. 
Unlike the continuous flow-through rinsing approach whereby cells experience shear 
force due to the flow, DropArrayTM Accelerator’s shaking approach minimizes shear 
stress at the bottom of the DropArrayTM plate, thus enabling cell-friendly rinsing.  
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The cell loss due to multiple rinsing steps that could arise from the HCS 
protocol was characterized [10]. Liver hepatoma cells, HepG2, transfected with GFP, 
were seeded on DropArrayTM plate, and imaged for cell loss due to multiple rinsing at 
the end of the fixation and permeabilization steps. Each of the fixation and 
permeabilization steps included 2 additional rinses to dilute the buffers, totaling 6 
rinses at the end of the permeabilization step. After permeabilization, the 
DropArrayTM plate underwent 15 rinses on the DropArrayTM Accelerator, and the 
spots were again imaged for comparison after the 5th, 10th and 15th rinse. The images 
were taken at various intervals and processed by ImageJ software (National Institute 
of Health, Bethesda, Maryland, USA) for cell count (Fig. 3.1) [15].  
Typically, HCS assays would require about 14 rinses depending on the 
protocol of the assay. However, our experiment involved 16 rinses from the fixation 
step, which was more rigorous that the usual protocol. Negligible cell loss was 
observed in this rinsing experiment. Among the various reagents applied in HCS, the 
permeabilization buffer was most likely to contribute to cell loss. This was because 
the Triton X-100 would chemically disrupt the cellular adhesion proteins [16], 
weakening the cells’ adhesion to the spot surface. However, despite 15 rinses on 
DropArrayTM Accelerator after cell permeabilization, over 98% cell retention was 
achieved on the DropArrayTM plate. This demonstrated that the gentle rinsing on the 
DropArrayTM Accelerator was well suited for conducting miniaturized HCS assays. 








Fig. 3.1. Cell count of 10 spots in the DropArrayTM plate after 21 rinsing steps on the 
DropArrayTM Accelerator. Control comprised of images from 10 spots before rinsing. 
Fixation (Fix) and permeabilization (Perm) steps were accompanied with 2 rinses 
before imaging, totaling 6 rinsing steps. Subsequently, additional 15 rinsing steps 
were implemented and imaged at intervals of 5 rinses. Over 98% of the cells remained 
attached to the spots of the DropArrayTM plate even after 21 rinses. 
 
3.3.1.3 Fine Tuning of Rinsing Duration on DropArrayTM Accelerator for ERK 
Translocation HCS assay 
The HCS assays involving molecular translocation bioapplication are 
particularly sensitive to the quality of rinsing. This is because the fluorescence 
intensity of the tagged protein is used to estimate the amount of protein within the 
different organelles of the cells. Thus, adequate rinsing is essential to ensure the 
removal of unbound antibodies to reduce non-specific bindings.  
By tuning the rinsing duration on the DropArrayTM Accelerator, the 
fluorescence signal difference between treated and negative control could be 
maximized, while reducing the coefficient of variation (CV) between replicates. In 
this study, the fluorescence signal of stained phosphorated-ERK was monitored upon 
treatment with phorbol ester phorbol 12-myristate 13-acetate (PMA). PMA stimulated 
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[18]. Phosphorated-ERK in the nucleus would be confirmed by the co-localization of 
the Hoechst and ERK stains. Hence, by taking the difference in the fluorescence 
intensity in the nucleus versus the cytoplasm, the relative amount of translocation 
could be compared to the negative control to obtain the dose response characteristics.  
NIH3T3 cells were treated with 100 ng/ml of PMA (positive control) for 30 
min, and stained for phosphorated-ERK. The difference in fluorescence signal 
between the positive control and the untreated cells, as well as the CV of the positive 
control for each shaking condition were measured and summarized in Table 3.1.  
 
Table 3.1. Effects of varying shaking time during parallel rinsing on DropArrayTM 
Accelerator on the fluorescence signal difference, CV of the positive control, and Z’ 









Range of fluorescence 
signal difference, D 
(R.F.U.) 
Range of CV of the 
positive control well (%) 
Range of Z’ 
factor 
5 80–100 15–25 -0.21–0.14 
10 110–135 15–20 -0.06–0.66 
15 150–165 12–15 0.62–0.82 
20 130–150 10–15 0.48–0.61 
 
The quality of the assay can be characterized by the Z-prime (Z’) factor [19], 
which measures the statistical spread of the data with reference to its standard error. 
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marginally stable if the Z’ factor is 0–0.5. An assay with a Z’ factor below 0 has 
positive and negative controls that are unstable (i.e. not meaningful). Generally, the 
difference in fluorescence signal between the positive and the negative controls would 
contribute to a better Z’ factor. With increasing shaking time, the CV of the signal 
was observed to decrease, but the overall signal of the data was also reduced above a 
shaking time of 15 sec. This led to a lower Z’ factor at a long shaking time of 20 sec. 
Hence, for the implementation of the DropArrayTM Accelerator for HCS assays, the 
shaking time was optimized at 15 sec. 
 
3.3.2 Ensuring DropArrayTM’s Compatibility to Cellomics ArrayScan® HCS Imager   
Chapter 2 illustrated that the problem of reading the DropArrayTM plate on a 
standard plate reader was resolved. For analysis of the HCS assays using 
DropArrayTM plates, offsets in position could be easily adjusted by the Cellomics 
High Content Analysis (HCA) software before reading the entire DropArrayTM plate.
 To adapt DropArrayTM technology to HCS assays, we have to overcome the 
issue associated with autofluorescence from the PTFE layer on the DropArrayTM plate. 
The over-exposure of the PTFE surface upon excitation/emission at 488 nm/509 nm 
resulted in the failure of the high-content analysis software to accurately identify the 
background, and created problems in measuring the intensity of the tagged proteins 
(Fig. 3.2). 
 
   






Fig. 3.2. Fluorescence micrographs of the DropArrayTM plate and stained cells imaged 
with various different filters. (a) Image taken at a laser excitation/filter emission 
wavelength of 350 nm/375 nm displays only the cells. (b) Image taken at a laser 
excitation/filter emission wavelength of 488 nm/509 nm displays both the cells and 
the PTFE layer of the DropArrayTM plate. (c) Composite image of (a) and (b). 
 
The fluorescence emission spectrum produced by the DropArrayTM plate was 
examined further, and high fluorescence was found to be emitted at ~ 500 nm (Fig. 
3.3). This emission was close to the ArrayScan’s filter emission wavelength when 
DylightTM 488 was employed for HCS assays. To overcome this problem in the early 
developments of the DropArrayTM technology, the secondary antibody was changed 
to DylightTM 549 in conducting HCS assays. In such case, the emission filters used for 
ArrayScan were in the range of 600 nm, which was predicted to minimally affect the 
HCS assays (see Fig. 3.3). Specifically, DylightTM 549 was used for the development 
of the mitotic index assay on DropArrayTM. 
Although the autofluorescence in DropArrayTM plate could be easily overcome 
by changing the secondary antibody, this would limit the application of the 
DropArrayTM technology since HCS assays that involved tagging 3 proteins and 
multiplexed assays would not be possible on DropArrayTM. To overcome this issue, 
various approaches were explored, including adopting different types of PTFE layer. 
Eventually, we arrived at a simple, yet robust solution to reduce the field of view of 
(a) (b) (c) 
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each spot on the DropArrayTM plate. By changing the objectives of the lens of the 
ArrayScan imager from 4× to 10×, the HCA software would have minimal detection 
of the PTFE layer. Hence, it was able to process the background correctly for any 
choice of secondary antibody used. This method was applied in the development of 









Fig. 3.3. Emission spectrum of the PTFE layer on the DropArrayTM plate with an 








Fig. 3.4. Change in objective from 4× to 10× effectively reduced the field of view for 
the spots on the DropArrayTM plate to avoid recognizing the background fluorescence 
of the DropArrayTM plate. 
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Besides producing robust data for HCS assays, the DropArrayTM technology 
facilitated data processing by imaging only one field per data point. In contrast, the 
ArrayScan imager required at least 16 fields to capture the entire well at 10× 
magnification for the 96-well plates. Thus, DropArrayTM technology enabled 
significant savings in the processing time and data storage of high-quality 
micrographs.  
 
3.3.3 Miniaturization of the ERK Protein Translocation Assay Using the 
DropArrayTM Technology  
The ERK protein translocation assay is a popular HCS assay because of the 
relevance of this pathway to cancer malignancies [20]. Studies have demonstrated that 
the translocation of ERK 1 and 2 (also known as p44 and p42 MAPK) from the 
cytoplasm to nucleus regulates mitosis and other cellular functions [21–23]. Therefore, 
there has been much interest to investigate novel growth factors and mitogens against 
cancer cell proliferation that can be potent inhibitors against the translocation of ERK 
1 and ERK 2 from the cytoplasm to the nucleus [24].  
Chang et al. have demonstrated the translocation of phosphorated-ERK 1/2 
from the cytoplasm to the nucleus upon stimulation by PMA via Western blot [18]. 
However, the cumbersome approach in sample preparation to isolate the contents of 
the nucleus and cytoplasm often leads to false negatives or positives. The ERK 
translocation high-content assay overcomes these limitations by analyzing the 
fluorescence micrograph of stained-ERK and nucleus. 
By applying the optimized protocol for the DropArrayTM Accelerator, we 
conducted the ERK translocation assay after mouse fibroblast NIH3T3 cells were 
treated with different concentrations of PMA for 30 min. Fig. 3.5 depicts the 
fluorescence micrographs of NIH3T3 cells stained for phosphorated-ERK 1/2 and 
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nuclei in the DropArrayTM plate and the 96-well plate. Although the background 
fluorescence from the 96-well plate data seemed higher as compared to the 
DropArrayTM plate, ERK 1/2 was observed in the nuclei region when the cells were 











Fig. 3.5. Fluorescence micrographs of NIH3T3 cells untreated or treated with PMA in 
DropArrayTM and 96-well plate for 30 min. Phosphorated-ERK protein translocation 
from the cytoplasm to the nucleus was tracked and illustrated by the green 
fluorescence. Cells were counterstained with Hoechst. 
 
The micrographs derived from the two platforms were analyzed by the 
Cellomics high-content analysis software to compute the translocation index. 
Subsequently, the indices were plotted on the same axes for comparison. It was 
observed that dose responses derived from the DropArrayTM plate and the 96-well 
plate have similar EC50 values of 2.3 ng/ml and 2.6 ng/ml of PMA, respectively, 
which were within the acceptable EC50 range of 1–6 ng/ml of PMA as published [22–
23]. The Z’ factor for the 96-well plate (-0.21) was much poorer as compared to that 
of the DropArrayTM plate (0.54). This demonstrated the DropArrayTM Accelerator’s 
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parallel rinsing capability in maximizing signal difference in HCS assays, thus 









Fig. 3.6. Drug response of NIH3T3 cells to PMA treatment. Assays conducted in (g) 
DropArrayTM plate with 500 cells and (g) 96-well plate with 5,000 cells produced 
drug response of similar EC50 values. Values are mean ± standard deviation; n = 4. 
 
3.3.4 Increased Rate of Antibody Binding Reaction Due to Miniaturization  
Often, in miniaturized assays, the rate of reaction increases due to the 
increased proximity between molecules [25]. As a result of the reduced distance 
between molecules, equilibrium could be established more quickly [26–28]. This 
suggests that primary and secondary antibody incubation times might be significantly 
reduced using DropArrayTM technology without compromising the assay quality.  
To investigate this hypothesis, we compared the performance of the ERK 
translocation assay between the 96-well plate and DropArrayTM plate by 
systematically reducing the primary and secondary antibody staining times. The ERK 
translocation assay was best suited for this study because of the stringency of the 
antibody binding on obtaining a meaningful EC50 value. A significant difference in 
the dose response was observed in the 96-well plate assay when the incubation times 
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of primary and secondary antibodies were reduced to 20 min; the intensity of the 
fluorescence-tagged ERK was not sufficient to produce a meaningful EC50 value (Fig. 
3.7). In contrast, a reasonable EC50 value of 2.9 ng/ml was obtained using the 
DropArrayTM plate assay (Fig. 3.8), indicating that equilibrium was achieved in 20-









Fig. 3.7. Drug response of NIH3T3 cells to PMA treatment. Assay conducted in 96-
well plate with reduced antibody staining time failed to produce an acceptable EC50 









Fig. 3.8. Drug response of NIH3T3 cells to PMA treatment. Assay conducted in 
DropArrayTM plate with reduced antibody staining time remained robust with an 
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Taking into account of the entire protocol (fixation, permeabilization, primary 
and secondary antibodies staining, and all intermediate washing steps), the 
DropArrayTM technology was able to cut the assay time from 2.5 h to 1.5 h, without 
compromising the results of the assay. This represented a 40% saving in the 
immunoassay time.  
 
3.3.5 Effects of Reduced Cell Number on the Robustness of Mitotic Index HCS 
Assay Conducted Using DropArrayTM Technology  
The mitotic index assay is widely applied to elicit the characteristics of many 
chemotherapeutic compounds, including nocodazole, vinblastine, colchicine, 
paclitaxel and curacin [29–30]. These compounds eliminate cancer by initiating cell 
cycle arrest during mitosis. The ability to miniaturize the mitotic index assay using the 
DropArrayTM technology would make the platform attractive for drug screening 
applications. In this section, we studied the robustness of the mitotic assay upon 
significant reduction in the number of cells used in the assay. The feasibility of this 
technique would be very attractive for the screening against scarce cell samples. 
Compared to the 96-well plate, the scale of miniaturization for conducting 
HCS assays using the DropArrayTM technology was 50× in assay volume, and 10× in 
surface area. Thus, to ensure similar cell confluency on the array of spots in 
DropArrayTM plates, cells were seeded at one-tenth that of the 96-well plates. For 
example, in mitotic index high-content cell-based assay, 7,500 cells and 750 cells 
were used for each well of the 96-well plate and for each spot on the DropArrayTM 
plate, respectively. Miniaturization in sample size by 50× was also explored (i.e. 
applying only 150 cells to each spot of the DropArrayTM plate). The robustness of the 
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mitotic index assay conducted using the DropArrayTM technology was examined in 
reference to the 96-well plate. 
For the mitotic index assay, we applied Docetaxel, a popular anti-cancer drug 
used for targeting breast, ovarian, gastric and lung cancers [31–33], to gastric cancer 
cell line, MKN7. After 18 h of Docetaxel treatment, the cells were stained for 
phosphorated histone H3, a marker for cells undergoing mitotic arrest. Figure 3.9 
depicts the fluorescence micrograph of assays conducted with DropArrayTM plate and 
96-well plate, whereby MKN7 cells undergone 10 mg/ml of Docetaxel treatment were 
compared to the dimethyl sulfoxide (DMSO) control.   
From analyzing the micrographs of stained MKN7 cells after Docetaxel 
treatment, the dose responses for assays conducted with DropArrayTM plate and 96-
well plate are plotted in Fig. 3.10. It was interesting to note that both platforms 
demonstrated similar EC50 of ~ 0.3 mg/ml of Docetaxel, despite the significant 
reduction in cell number using the DropArrayTM technology. 
The compliance in assay performance could be attributed to the high 
activation percentage of mitotic cells in this assay, i.e. there were sufficient mitotic 
cells for detection even within a sample size of 150 cells. Also, the robustness in 
parallel rinsing on the DropArrayTM Accelerator ensured minimum cell loss in the 
assay, hence minimizing errors associated with the loss of mitotic cells. This study 
illustrated that the DropArrayTM technology would be useful for studying the dose 
response characteristics for scarce samples, which would be detailed in Chapter 4.  










Fig. 3.9. Fluorescence micrographs of MKN7 cells treated with Docetaxel for 18 h in 
DropArrayTM plate and 96-well plate. Phospho-histone H3 protein, an indicator of 
cells that underwent mitotic arrest was shown by the red fluorescence. Cells were 









Fig. 3.10. Drug response of MKN7 cells to Docetaxel treatment. Assays conducted in 
(g) DropArrayTM plate with 150 cells and (g) 96-well plate with 7,500 cells produced 
similar drug response profiles. Values were mean ± standard deviation; n = 4. 
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3.3.6 Caspase 3 HCS Assay for Studying Dose Response of Doxorubicin  
Doxorubicin is an anthracycline anti-cancer drug employed in the 
chemotherapeutic treatment of breast, liver, pancreatic and colon cancers [33]. It is 
therefore of great interest to characterize its efficacy towards the various cancers [34]. 
By understanding the autofluorescence properties of doxorubicin [35], we aimed to 
develop a robust HCS assay to demonstrate the dose response of doxorubicin in drug 
treatment experiments. This assay would then be applied in Chapter 4 to study scarce 
cancer stem-like cells that persist in the hepatoma carcinoma cell line, HuH7. 
 
3.3.6.1 Effect of the Autofluorescence of Doxorubicin on HCS Assays  
The autofluorescence of doxorubicin can affect the HCS assays readout even 
after the compound has been washed out. Kellogg et al. have demonstrated that 
doxorubicin functionally intercalates the deoxyribonucleic acid (DNA) to prevent cell 
replication [36]. Hence, doxorubicin resides within the cellular nucleus and causes 
interference when reading stained proteins at various emission frequencies.  
To tackle this problem, the emission spectrum of doxorubicin (10 mg/ml) was 
obtained at an excitation wavelength of 340 nm (Fig. 3.11) [10]. The doxorubicin 
emission peaks at 600 nm, which is likely to interfere with the fluorescence emissions 
of the fluorescent tags applied in most Cellomics HCS assays. When DylightTM 488 
and 549 were employed as secondary antibodies, the corresponding filter emissions 
on the ArrayScanTM HCS imager were 550 nm and 650 nm, respectively, hence these 
antibodies were not suitable to tag the proteins of interest. To prevent interference due 
to the autofluorescence from doxorubicin, the secondary antibody applied in HCS 
assay should match the emission filters of the ArrayScan (i.e. with fluorescence 
emissions at wavelengths above 700 nm).  
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To verify the choice of emission filters for HCS assays, the hepatoma 
carcinoma HuH7 cells were treated with 10 mg/ml of doxorubicin for 8 h, and scanned 
under various filter settings to detect autofluorescence from the HuH7 cells. Indeed, 
we found that only filters emitting fluorescence in the ranges of 375–425 nm (XF100) 
and 700–750 nm (XF93) showed negligible autofluorescence from HuH7 cells. These 
allowed us to perform HCS assays by staining cellular nuclei using Hoechst dye and 
tagging of the protein of interest using Alexa Flour 649TM.  
 







Fig. 3.11. Emission spectrum of doxorubicin in water (excitation wavelength = 380 
nm).  
 
 3.3.6.2 Development of the Caspase 3 HCS Assay to Elicit the Drug Response of 
Doxorubicin  
Doxorubicin is a potent chemotherapeutic drug known to trigger apoptosis in 
many different types of cancer cells [34]. Eom et al. demonstrated that doxorubicin 
activates the Caspase 3 pathway to induce apoptosis in HuH7 cells [37]. Hence, we 
were interested to elicit this characteristic in an HCS assay, and later apply this 
screening assay against cancer stem-like cells in Chapter 4. The presence of cleaved 
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Caspase 3 in HuH7 was confirmed by Western blot when HuH7 cells were treated 








Fig. 3.12. Cleaved Caspase 3 detected in HuH7 cells after treatment with doxorubicin 
for 18 h.   
 
Tapping on the experience in optimizing HCS protocols on DropArrayTM 
platform, we have developed the high-content Caspase 3 assay. Fig. 3.13 depicts the 
fluorescence micrographs of HuH7 cells stained from cleaved Caspase 3 protein after 
18 h of doxorubicin treatment. The significant increase in the number of cells stained 
for cleaved Caspase 3 correlated to the Western blot results. The micrographs were 
analyzed by the HCA software to derive the dose response characteristic of EC50 = 3 
mg/ml. This assay would be very useful to study dose response of scarce cell samples, 





DMSO        10 mg/ml of 
Control       Doxorubicin   







Fig. 3.13. Fluorescence micrographs of HuH7 cells treated with DMSO (control) and 
doxorubicin. Cleaved Caspase 3 protein, an indicator of cells arrested at apoptosis due 










Fig. 3.14. Drug response of HuH7 cells to doxorubicin treatment. HuH7 cells undergo 
Caspase 3 activation at a doxorubicin dosage of > 1 mg/ml. Values are mean ± 
standard deviation; n = 4. 
 
3.4 Summary 
While miniaturization of HCS assays offers the potential to reduce cost and 
assay duration, and increase efficiency in data management, there are several inherent 
challenges in adopting the microarray/microfluidics platform for HCS assays. These 
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challenges include cell loss due to multiple rinsing steps in HCS assays, poor 
compatibility to HCS imaging platforms, and limited applicability of the miniaturized 
assay platforms to other HCS assays. This study demonstrated that the DropArrayTM 
technology could overcome the various challenges to provide convenient 
miniaturization of HCS assays. The HCS assays remained robust at reduced assays 
volume and cell numbers. Thus, DropArrayTM technology helped to save reagents, 
samples, and assay time. Furthermore, data analysis, management and storage of 
high-quality micrographs could be greatly reduced since only one field would be 
imaged for each spot on the DropArrayTM plate. The DropArrayTM technology was 
applied successfully to the Caspase 3 high-content assay to avoid the autofluorescence 
of doxorubicin, so as to elucidate the drug response. This example illustrated our 
ability to miniaturize useful HCS assays using the DropArrayTM technology. 
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Chapter 4 - Application of DropArrayTM Platform for Studying Drug Resistance 
of Scarce Cancer Stem Cells 
 
4.1 Introduction 
The treatment of cancer has shifted its focus to target cancer stem cells (CSCs), 
which are capable of escaping chemotherapy [1] and driving tumor growth by 
metastasis [2]. It is thus necessary to isolate these aberrant cells, identify their 
biological properties, and develop specific therapies targeting them. However, the 
scarcity of the CSCs severely limits the ability to screen and characterize them [3]. 
Since standard protein-based studies such as Western blot are not sensitive enough to 
detect signals from less than 50,000 cells per experiment [4], studying the protein 
expressions of CSCs would be a major challenge. 
Besides sample scarcity, the lack of specific choice of marker for CSCs adds 
to the complexity in identifying and isolating these cells. For example, although 
CD133+ colon cancer tumor cells are commonly enriched as CSCs [5], Dalerba et al. 
observed that expressions of CD133 displayed varied patterns in colon carcinoma 
incidents [6]. This resulted in an impure population of enriched CSCs, as compared to 
using CD44+/Lin-/ESA+. Also, surface markers, which are commonly used for 
enriching CSCs, have little relevance to the cellular function of CSCs [7]. There is 
therefore no guarantee that a pure population of CSCs can be isolated even when 
commonly designated surface markers are used. 
 Isolating CSCs based on their functional or behavioral characteristics may be 
more meaningful. CSCs are known to escape chemotherapy due to their drug 
resistance and efflux capabilities [8]. Hence, to minimize conflicts in the choice of 
surface markers, enriching CSC population based on Hoechst efflux characteristics 
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(or side population cells (SP)) would likely yield a more representative CSC 
population for drug screening and development. SP cells show increased expressions 
of genes related to drug resistance, including ATP-binding cassette, sub-family G, 
member 2 (ABCG2) and multiple drug resistance, member 1 (MDR1) [8]. Several 
human cancers including leukemia, breast, lung and brain, and various cancer cell 
lines found SP-enriched CSCs with high tumorgenicity and stem-like characteristics 
[9–11]. Since SP-enriched stem cells are rare (0.1–5%), it is challenging to 
characterize their drug response [12].   
Even within cancer cell lines, there is a lack of convincing data to demonstrate 
the drug resistance properties of SP-enriched CSCs. Haraguchi et al. showed that in 
hepatoma carcinoma HuH7 cells, SP cells exhibited higher cell viability as compared 
to HuH7 non-SP cells when treated with a variety of chemotherapeutic compounds, 
suggesting the drug resistance of HuH7 SP cells [13]. However, in the same 
experiment, there was also a substantial decrease in HuH7 SP viability after drug 
treatment (for example, a 60% decrease in HuH7 SP cell viability was noted when 
treated with gemcitabine) [13]. Similarly, Ho et al. claimed drug resistance in SP cells 
from various lung cancer cell lines when the SP cells only demonstrated, on average, 
a less than 50% increase in IC50 values as compared to non-SP cells upon drug 
treatment [14]. It was noted in both cases that the authors had not verified the purity 
of their SP-enriched CSCs. Indeed, Haraguchi et al. acknowledged that the pre-gating 
criterion for SPs was not stringent to allow for more SP cells to be collected for the 
cell-based assays [13]. An approach for elucidating the drug resistance characteristics 
of scarce SP-enriched CSCs is yet to be established. 
We have demonstrated the flexibility of the DropArrayTM platform in high-
content cell-based assays, using only 500 cells per data point. To overcome the 
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challenges of sample scarcity commonly faced in biomedical research, the 
DropArrayTM platform was used to study the SP cells. Herein we demonstrated our 
ability to enrich SP cells of high purity, and investigated the cancer stem-like 
characteristics of SP cells [15]. We also custom miniaturized high-content screening 
(HCS) assays to elucidate the drug resistance characteristics of these SP-derived 
CSCs [15]. 
 
4.2 Experimental Methods 
4.2.1 Materials 
Various cancer cell lines including those of liver (HuH7 and HepG2), breast 
(MCF7), colon (HCT116 and SW480) and cervix (HeLa) were obtained from 
American Type Culture Collection (ATCC) (Manassas, MA, USA), and cultured in 
the recommended medium containing 1% of penicillin/streptomycin and 10% of heat-
inactivated fetal bovine serum (FBS) (Invitrogen-Life Technologies, Carlsbad, CA, 
USA). Mitotic index and oxidative stress high-content screening assay kits were 
purchased from Thermo Scientific Cellomics (Pittsburgh, PA, USA). Caspase 3 assay 
for HCS was developed in-house using the following reagents: phosphate buffered 
saline (PBS), 37% formaldehyde solution, Triton-X 100 and albumin from bovine 
serum albumin (BSA) (all from Sigma Aldrich, St. Louis, MO, USA), cleaved 
Caspase 3 antibody (BD Bioscience, San Jose, CA, USA) and goat-anti-rabbit IgG 
Alexa Fluor 647 (Invitrogen-Life Technologies, Carlsbad, CA, USA).  
 
4.2.2 SP Analysis and Enrichment  
SP cells were enriched from HuH7, MCF7 and SW480. During preparation for 
Hoechst staining, cells were trypsinized from two T175 culture flasks using Accumax 
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(Innovative Cell Technologies, Inc., San Diego, CA, USA), and subsequently 
resuspended at 37°C in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen-
Life Technologies, Carlsbad, CA, USA) containing 2% of FBS and 1 mM of 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Invitrogen-Life 
Technologies, Carlsbad, CA, USA) at a concentration of 1×106 cells/ml. The cells 
were then labeled with Hoechst 33342 (Sigma Aldrich, St. Louis, MO) at a 
concentration of 5 g/ml, and incubated for 60 min at 37°C, either alone or with 50 mM 
of verapamil (Sigma Aldrich, St. Louis, MO, USA). After staining, the cells were 
suspended in Hanks’ balanced saline solution (HBSS) (Invitrogen-Life Technologies, 
Carlsbad, CA, USA) containing 2% of FBS and 1 mM of HEPES at a concentration 
of 6×106 cells/ml, passed through a 40-mm cell stainer (BD Falcon), and maintained at 
4°C until flow cytometry. Cells were counterstained with 1 g/ml of propidium iodide 
(Invitrogen-Life Technologies, Carlsbad, CA, USA) to label dead cells just before 
analysis, and sorted using the BD FACS Aria (Becton, Dickinson). The Hoechst dye 
was excited at 350 nm, and its fluorescence was measured at two wavelengths using a 
450/50-nm band-pass filter and a 670-nm long-pass edge filter. The gating criteria 
were stringent to ensure that only viable single cells were analyzed and sorted. Upon 
sorting, the SP and non-SP cells were resuspended in fresh culture media or PBS for 
seeding onto the DropArrayTM plate or for quantitative real-time polymerase chain 
reaction (PCR) experiments, respectively.  
 
4.2.3 Gene Expression Profile 
The gene expressions of drug resistance genes, ABCG2 and MDR1 were 
compared in both the SP and non-SP cells enriched from HuH7, SW480 and MCF7 
using the TagMan Gene Expression Cells-to-CT kit (Applied Biosystems, Ambion, 
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Austin, TX, USA). Cell lysis, reverse transcription (RT) and real-time PCR were 
performed according to the manufacturer’s instruction. PCR amplifications were 
conducted using the iQ5 iCycler (BioRad, Philadelphia, PA, USA) for the following 
gene identification codes (Applied Biosystems, Foster City, CA), ABCG2 
(Hs01053790_m1) and MDR1 (Hs00427805_g1), using GAPDH (Hs99999905_m1) 
as the reference gene. The cycle threshold value, which was determined using second 
derivative, was used to calculate the normalized expression of the indicated genes 
using the iQ5 Optical System Software.  
 
4.2.4 In Vivo Tumorigenic Experiments  
In vivo experiments were performed in accordance with the institutional 
guidelines and compliant to the IACUC guidelines (IACUC Number 080369) for the 
use of laboratory animals. 3,000 SP and non-SP cells from HuH7 were 
subcutaneously injected into the right and left flanks of the BALB/c mice, 
respectively. The mice were sacrificed at day 60 or when the tumors had grown to a 
maximum of 10 mm. Tumor volume was calculated using the formula 0.52 × length × 
width × 2. The tumors were surgically removed, and a portion was digested in 0.1 
Wünsch units/mL of collagenase according to the manufacturer’s instructions before 
reanalysis by the Hoechst 33342 dye efflux assay as described above. The excised 




4.3 Results and Discussion 
4.3.1 SP Cells in Cancer Cell Lines 
A number of cancer cell lines consistently possesses SP phenotypes that 
exhibit cancer stem-like characteristics. These include esphageal cancer (TE1, TE2, 
TE13), gastric cancer (NUGC3, MKN1, MKN7, MKN28), colorectal cancer (WiDR, 
CCK81, Colo201, Colo205, SW480), liver cancer (Hep3B, HuH7), pancreatic cancer 
(PK9, PK45H), and breast cancer (MCF7, MDA231) [13–14, 16–17]. Herein SP cells 
from the hepatoma carcinoma HuH7, colorectal carcinoma SW480 and breast 
adenocarcinoma MCF7 were enriched and characterized. 
 
4.3.1.1 Identification of SP Cells in Cancer Cell Lines 
Staining and analyzing the Hoechst efflux profile of cells can be complex and 
skill-dependent [18], thus we verified our technique by analyzing cell lines with and 
without SP cells. Patrawala et al. demonstrated the absence of SP cells in Hela [16]; 
hence, these cells could be used as an ideal negative control for our experiment (Fig. 
4.1). In Hoechst staining profiles, the tail at the bottom left of the plot represents a 
population of cells capable of Hoechst efflux, gated as SP cells. The positioning of SP 
gates can be confirmed with the additional treatment of verapamil, a calcium ion 
influx inhibitor [19], which blocks SP cells from pumping out Hoescht dye. Fig. 4.1 
depicts the Hoechst staining profile of Hela, indicating the absence of SP phenotype 
in Hela. This verified that our staining and gating strategies would not include stray 
fractions of cells that resembled the genuine SP phenotype. 
We then investigated for the presence of SPs in HuH7, MCF7 and SW480. 
These SP phenotypes were chosen because they exhibit cancer stem cell 
characteristics, including tumorgenicity and increased expressions of multi-drug 
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resistance genes. In agreement with the findings of Haraguchi et al., Yamazaki et al. 
and Engelmann et al. [13, 20–21], we found small, but reproducible quantities of SP 
cells in HuH7, MCF7 and SW480 (0,7%, 1.2% and 0.3% of each cell population, 









Fig. 4.1. (a) SP analysis of human cervical carcinoma Hela. The missing characteristic 
tail in the Hoechst staining profile in Hela suggests the absence of SP phenotype. (b) 
Control for Hoechst staining profile with the additional treatment of verapamil to 
prevent Hoechst efflux. 
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Fig. 4.2. (a) Analysis of SP in hepatoma carcinoma cell line HuH7 SP cells from the 
fluorescence intensity of Hoechst 33342 staining. SP population was represented by 
the tail of the Hoechst staining profile, which was ~ 0.7% of the viable single cell 
population. (b) Treatment of verapamil prevented Hoechst efflux, causing SP to 









Fig. 4.3. (a) Analysis of SP in human breast adenocarcinoma cell line MCF7 SP cells 
from the fluorescence intensity of Hoechst 33342 staining. SP population was 
represented by the tail of the Hoechst staining profile, which was ~ 1.2% of the viable 
single cell population. (b) Treatment of verapamil prevented Hoechst efflux, causing 
SP to disappear into the bulk population.  
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Fig. 4.4. (a) Analysis of SP in human colorectal carcinoma cell line SW480 SP cells 
from the fluorescence intensity of Hoechst 33342 staining. SP population was 
represented by the tail of the Hoechst staining profile, which was ~ 0.3% of the viable 
single cell population. (b) Treatment of verapamil prevented Hoechst efflux, causing 
SP to disappear into the bulk population.  
 
4.3.1.2 Purity of SP Cells After Flow Cytometry Sorting  
For the flow cytometry sorting of SP cells, we implemented stringent gating 
criteria to exclude dead cells and doublet cells. To investigate the purity of the sorted 
SP and non-SP cells, we conducted post-sorting analysis of the two sorted populations. 
Fig. 4.5(a) depicts Hoechst staining profiles of the sorted HuH7 SP cells without 
contamination from the non-SP fraction. Likewise, for the HuH7 non-SP cells, we did 
not observe any contamination from the SP cells. This confirmed that our staining 
protocol and gating criteria allowed for the collection of pure SP and non-SP cells.   
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Fig. 4.5. Post-sorting analysis of HuH7 (a) SP and (b) non-SP cells. No 
contaminations from each of the populations were observed, confirming the purity of 
the sorted SP and non-SP populations.  
 
4.3.1.3 DropArrayTM Enabled Studies with Scarce SP-Enriched CSCs  
Despite the use of cell lines in our experiments, the amounts of SP cells 
obtained remained scarce. Theoretically, cell lines can be cultured in abundance and 
would therefore mean an unlimited supply of SP cells. However, this is not practical 
as the yield of the SP cells is limited by two factors: duration of sorting by flow 
cytometry and purity of the sorted cells.  
To ensure the viability of the enriched SP cells for further experiments, the 
number of SP cells enriched was restricted by the duration of the sorting experiment. 
In a typical experiment, for a starting sample of 25 million cells, it would take ~ 6 h to 
enrich less than 50,000 cells. Since the DropArrayTM platform would only require 500 
cells per data point, we were able to overcome the issue of SP cell scarcity to study 
their drug resistance properties using standard in vitro assays. If the assays were 
conducted in 384-well plates, we would require 5 times more cells to perform the 
same experiment.  















In addition, it is critical to minimize contamination from non-SP cells in the 
SP fraction, and vice-versa. This is because the success in in-vitro drug screening 
experiments will be largely dependent on the purity of the SP cells enriched. Hence, it 
would be important to implement stringent gates to exclude non-viable cells as well as 
doublet cells. In experiment whereby SW480 SP cells were enriched (0.2% gated as 
SP cells), there was only ~ 1 SP cell in every 1,300 tumor cells, i.e. only less than 
20,000 SW480 SP cells were obtained for each experiment when sorting from 25 
million SW480 cells (Fig. 4.6). To ensure purity of the enriched SP cells, there was a 
trade-off in the yield of SP cell-sorting process.  
 
 
Fig. 4.6. Breakdown of cell population from FACS Aria Software during SW480 SP 
cell sorting.  
 
4.3.2 Characterization of HuH7 SP Cells as Cancer Stem Cells 
CSCs are defined as a rare cell population in cancer, which behaves like stem 
cells and is the cell population that is responsible for tumor growth and metastasis 
[22]. Tumorigenic characteristics are demonstrated by the SP-enriched CSCs from 
breast, colon, pancreatic and liver cancers and leukemia. HuH7 SP cells have been 
well-characterized for their cancer stem cell properties [13, 23].  Chiba et al. 
demonstrated that only the HuH7 SP cells (and not the HuH7 non-SP cells) were 
capable of initiating tumors when subcutaneously inoculated into non-obese 
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diabetic/severe combined immunodeficiency (NOD/SCID) mice [23]. Haraguchi et al., 
on the other hand, noted that HuH7 SP cells displayed chemoresistance to anticancer 
agents including doxorubicin, 5-fluorouracil and gemcitabine, in contrast to the HuH7 
non-SP cells. Also, HuH7 SP cells possessed increased expressions of ABCG2 and 
MDR1, which were related to drug transporter mechanisms [13].  
To examine if the HuH7 SP cells enriched by us exhibited the characteristics 
of CSCs, their tumorigenic properties in BALB/c nude mice were investigated. 3,000 
HuH7 non-SP and SP cells were inoculated subcutaneously in the left and right flanks 
of each mouse, respectively. After 6 weeks of transplantation, out of two in three mice, 
sites inoculated with the HuH7 SP cells were capable of initiating tumors, while 
tumors were not initiated by the HuH7 non-SP cells (Fig. 4.7). This confirmed that the 











Fig. 4.7. 3,000 HuH7 SP cells were sufficient to initiate tumors when inoculated 
subcutaneously in BALB/c nude mice, unlike the HuH7 NSP cells.  
 
Right side (SP) 
Mouse 2 
Left side (NSP) 
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Left side (NSP) 
Right side (SP) 
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4.3.2.1 Repopulation of HuH7 SP Cells in Solid Tumor from Transplantation 
During metastasis, CSCs are known to demonstrate self-renewal capabilities 
by repopulating the entire tumor with non-CSCs, whilst maintaining a sub-population 
of CSCs [24]. To investigate this phenomenon, a portion of the HuH7 SP induced 
tumors was obtained from the inoculation experiment. The tumor cells were purified, 
and SP analysis was conducted as mentioned in 4.2.2. It was interesting to note that 
the tumor generated by inoculating a pure population of HuH7 SP cells into the 
BALB/c mice possessed only 0.3% of SP phenotype (Fig. 4.8). This was less than the 
original 0.7% SP found in standard tissue culture methods. The discrepancy could be 
due to the difference in culture conditions. Cancer stem cells usually remain quiescent 
in microenvironment [24]. However, during the growth of the tumor, there was a need 
for the generation of fast-growing tumor cells from HuH7 SP cells, hence resulting in 
a lower percentage of HuH7 SP cells. This also demonstrated the self-renewal 








Fig. 4.8. SP analysis of tumor cells from sites inoculated with HuH7 SP cells. (a) 
Tumor cells harvested from BALB/c mice possessed 0.3% of SP population. (b) 
Treatment of verapamil prevented Hoechst efflux, causing SP to disappear into the 
bulk population, confirming the SP gating criteria.  
Hoechst 33342 a 













b Hoechst 33342 + verapamil 
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4.3.2.2 Histological Analysis with H&E Staining  
Angiogenesis is another characteristic of CSCs [24]. H&E staining of 
histological sections of the tumor showed the presence of blood vessels beneath the 
skin epithelial layer (Fig. 4.9). This illustrated that the HuH7 SP-induced tumor was 
capable of inducing blood vessel formation to supply nutrients within the tumor, 





Fig. 4.9. H&E staining of a section of tumor induced by HuH7 SP cells. The arrows 
pointed to the blood vessels formed under the skin epithelial layer, indicating 
angiogenesis of HuH7 SP cells. 
 
4.3.3 Drug Resistance Properties of SP Cells of HuH7, MCF7 and SW480 
To study the drug resistance characteristics of SP cells enriched from HuH7, 
SW480 and MCF7, expression levels of the drug efflux transporters, ABCG2 and 
MDR1, were analyzed for each of the SP and non-SP phenotypes by real-time PCR. 
ABCG2 and MDR1 play a major role in the drug resistance [25], belonging to a class 
of ATP-binding cassette (ABC) transporters shown to restrict absorption of anticancer 
drugs such as methotrexate, topotecan, mitoxantrone, and doxorubicin [26–29]. 
In addition, we miniaturized HCS assays to study the drug response of each of 
the SP phenotypes. With the flexibility of the DropArrayTM platform in miniaturizing 
HCS assays, the drug activities of SP-enriched CSCs in 3 different HCS assays were 
investigated.  
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4.3.3.1 Characterizing Drug Resistance Properties of HuH7 SP Cells  
Our HuH7 SP cells were observed to show ~ 2- and 3-fold increase in 
expression levels of ABCG2 and MDR1, respectively (Fig. 4.10). This agreed with 







Fig. 4.10. Characterization of drug resistance genes, ABCG2 and MDR1, in HuH7 (g) 
SP and (g) non-SP cells by quantitative real-time PCR using 3,000 cells per replicate. 
Values were mean ± standard deviation; n = 4.  
 
To further characterize the chemoresistance in HuH7 SP cells, we 
miniaturized Caspase 3 assay to study the effects upon doxorubicin treatment. There 
were two main limitations in Haraguchi et al.’s study to demonstrate the 
chemoresistance of doxorubicin in HuH7 SP cells [13]. The half-life of doxorubicin is 
12–20 h. Hence, the 72-h treatment of doxorubicin in Haraguchi et al.’s experiment 
had little relevance to the required dosage under clinical conditions. Moreover, the 
biological activity of doxorubicin should ideally be elicited using cell-based assays 
(given the biological relevance of the drug), instead of the MTT cell proliferation 
assay (since it would be difficult to understand the activity of the drugs using MTT 
assays). Since Eom et al. showed that doxorubicin triggered Caspase 3 pathway to 









































miniaturized Caspase 3 HCS assay to elucidate the drug resistance properties of HuH7 
SP cells. 
After 18 h of doxorubicin treatment, the HuH7 SP and non-SP cells were 
subjected to miniaturized Caspase 3 HCS assays on the DropArrayTM platform. Fig. 
4.10 shows the immunofluorescence micrographs of HuH7 SP and non-SP cells 
treated with 100 mg/ml of doxorubicin, and stained for cleaved Caspase 3 protein (red) 
and nucleus (Hoechst). Fig. 4.12 shows that over 15% of HuH7 non-SP cells 
exhibited Caspase 3 activity at the EC50 value of doxorubicin (10 mg/ml). In contrast, 
HuH7 SP cells displayed negligible increase in Caspase 3 activity even when treated 
with up to 100 mg/ml of doxorubicin, indicating the poor efficacy of doxorubicin 







Fig. 4.11. Fluorescence micrographs of HuH7 SP and non-SP cells treated with 
doxorubicin for 18 h. Cleaved Caspase 3 protein, an indicator of cells arrested at 
apoptosis due to doxorubicin was shown by the red fluorescence. Cells were 
counterstained with Hoechst. 
 
This study demonstrated the application of miniaturized HCS assay for 
screening against CSCs. Compared to Haraguchi et al.’s findings where MTT assays 
were applied [13], we were able to show a more significant difference between the 
dose response of HuH7 SP and non-SP cells, suggesting that the miniaturized Caspase 
HuH7 non-SP HuH7 SP 
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3 assay produced a more sensitive set of data to illustrate the drug resistance 
properties of HuH7 SP cells. Since the HuH7 SP cells were demonstrated to be 
resistant towards doxorubicin, these cells would be a relevant CSC candidate to target 








Fig. 4.12. Drug response of HuH7 (g) SP and (g) non-SP cells to doxorubicin 
treatment. HuH7 SP cells demonstrated a much lower percentage of cells undergoing 
Caspase 3 activation as compared to the non-SP cells. Values were mean ± standard 
deviation; n = 4.  
 
4.3.3.2 Drug Resistance Properties in MCF7 SP Cells 
Drug resistance in MCF7 SP cells has been demonstrated by Patrawala et al. 
and Engelmann et al. MCF7 SP cells showed up-regulation of ABCG2 and MDR1 as 
compared to the non-SP cells [21, 31], along with tumorigenic properties and other 
stem cell characteristics. Herein we focused on validating our enriched MCF7 SP 
cells as CSCs. We found that ABCG2 and MDR1 expression levels were increased by 
11.6 ± 0.3 and 2.51 ± 0.8 folds, respectively, as compared to MCF7 non-SP cells (Fig. 
4.13). A suitable HCS assay was then applied to elucidate the drug response of the 
MCF7 SP cells.  
 


















































Fig. 4.13. (a) Expression levels of ABCG2 and MDR1 in MCF7 (g) SP and (g) non-
SP cells by quantitative real-time PCR using 3,000 cells per replicate. Values were 
mean ± standard deviation; n = 4. 
 
In adjuvant chemotherapy of breast cancer, docetaxel is widely used to 
eliminate the remaining cancer cells present in the patient after surgical removal of 
the tumor [32]. Since docetaxel targets rapidly proliferating cancer cells and induces 
cell cycle arrest during mitosis [33], we used the mitotic index assay for our study. 
The ability to destroy any remaining CSCs is critical to prevent metastasis at a later 
stage [2]. Thus, we were interested to study whether MCF7 SP cells were resistant to 
docetaxel treatment.  
The standard 100-ml high-content mitotic index assay was miniaturized to 2-ml 
assay using the DropArrayTM platform. In this assay, mitotic cells were stained 
positive for phosphorylated core histone protein H3 (green), which would be abundant 
in the nuclei of dividing cells, while the nuclei of the cells were stained with Hoechst 
(Fig. 4.14). The positively stained cells would represent the population of cells that 
were arrested in mitosis phase because of the efficacy of the stimulant, i.e. docetaxel.   
MCF7 SP and non-SP cells were treated with varying concentrations of 
docetaxel for 18 h. High-content image analysis of the fluorescence micrographs 



















treatment for the MCF7 SP cells, as compared to the non-SP cells (Fig. 4.15). The 
mitotic index of MCF7 SP cells remained at ~ 5%, even when treated with a high 
concentration of 100 mg/ml of docetaxel. This demonstrated that MCF7 SP cells 







Fig. 4.14. Fluorescence micrographs of MCF7 SP and non-SP cells treated with 100 
mg/ml of docetaxel for 18 h. Phosphorylated core histone protein H3, an indicator of 
cells arrested at mitosis phase due to docetaxel was shown by the green fluorescence. 











Fig. 4.15. Drug response of MCF7 (g) SP and (g) non-SP cells to docetaxel treatment. 
A lower percentage of the MCF7 SP cells underwent mitotic arrest, as compared to 
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4.3.3.3 Drug Resistance Properties of SW480 SP Cells 
The SW480 cell line was established from a primary adenocarcinoma of the 
colon of a 50-year-old patient. After surgical removal of that primary tumor, 
metastasis took place a year later at the lymph node, from which another cell line, 
SW620, was derived from the metastatic site [34]. Wang et al. demonstrated that the 
SW480-induced tumor grew more quickly than the SW620-induced tumor. 
Furthermore, SW480 was found to give rise to higher incidences of lung and liver 
metastases as compared to SW620 [35]. Coincidentally, SW480 possesses SP 
phenotypes characteristic of CSCs [13].  
We investigated the drug resistance of SW480 SP and non-SP cells. In 
agreement with our observations for the HuH7 SP cells and MCF7 SP cells, SW480 
SP cells showed increases in the expression levels of ABCG2 (by 5.1 ± 0.5 fold) and 












Fig. 4.16. (a) Expression levels of ABCG2 and MDR1 in SW480 (g) SP and (g) 
non-SP cells by quantitative real-time PCR using 3,000 cells per replicate. Values 




















4.3.3.4 Oxidative Stress in SW480 SP Cells 
Gao et al. demonstrated that SW480 cells underwent apoptosis when subjected 
to oxidative stress [36]. Under oxidative stress, the cAMP response element binding 
(CREB) protein expression decreased substantially [37], leading to cell death. Herein 
we miniaturized Cellomics’ high-content CREB activation assay from 100 ml to 2 ml 
using the DropArrayTM platform. 
We induced oxidative stress in SW480 SP and non-SP cells using varying 
concentrations of hydrogen peroxide (H2O2). Over 60% of SW480 SP cells expressed 
CREB protein even at 100 mM of H2O2, but only 5% of SW480 non-SP cells survived 
this treatment (Figs. 4.17 and 4.18). This demonstrated that SW480 SP cells have 














Fig. 4.17. Fluorescence micrographs of SW480 SP and non-SP cells treated with 100 
mM of H2O2 for 1 h. Phospho-CREB protein, an indicator of cells that survived 
oxidative stress was shown by the green fluorescence. Cells were counterstained with 
Hoechst. 
















Fig. 4.18. Drug response of SW480 (g) SP and (g) non-SP cells to H2O2 treatment. A 
greater percentage of SW480 SP cells were resilient against oxidative stress. Values 
were mean ± standard deviation; n = 4. 
 
4.4 Summary 
Due to a lack of biological relevance in standard MTT/MTS cell assays [13], it 
has been difficult to elucidate the drug response of scarce CSCs. We were the first to 
demonstrate protein-based studies using scarce CSCs. This was made possible 
through the miniaturization of high-content cell-based assays using the DropArrayTM 
platform. The proteins related to cellular survival and apoptosis were applied to only 
500 cells per data point. Hence, despite sample scarcity, we were able to elucidate the 
drug resistance properties of rare CSC-like cells. The DropArrayTM platform therefore 
has opened up the possibility of high-throughput screening with scarce CSCs in the 
search of chemotherapeutic compounds that would specifically target CSCs. Although 
Grupta et al. appeared to have overcome CSC scarcity thorough the immortalization 
and induction of the epithelial-mesenchymal transition (EMT) to increase the number 
of CSCs [3], the ability to study CSCs in their native state without any genetic 
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Chapter 5 – Recommendations for Future Work 
5.1 Advantages of the DropArrayTM Technology as Compared to Other Cell 
Microarrays 
In microarray platforms, the selective hydrophobic-hydrophilic patterned 
surface allows for convenient access of individual wells independently as in 96-well 
plates. However, one major pitfall is the loss of their selective hydrophobic-
hydrophilic characteristics after repeated rinsing due to surface wetting [1]. This 
phenomenon limits cell microarray applications to mainly reverse transfection assays 
[2, 3].  
The unique parallel rinsing strategy employed in DropArrayTM overcomes 
surface wetting even after repeated rinsing. Hence, this platform is suitable for 
conducting heterogeneous assays, such as high-content cell-based assays and enzyme-
linked immunosorbent assay (ELISA). In addition, the ability to retain its selective 
hydrophobic-hydrophilic patterned surface allows the DropArrayTM platform to use 
the minimum amount of cells required for the cell seeding process. Hence, the 
DropArrayTM platform is suitable for applications and assays involving scarce cells.  
 
5.2 Applications of the DropArrayTM Technology to Cancer Stem Cells Derived 
from Patients  
The DropArrayTM technology may one day be used for personalized medicine 
to ensure the efficacy of cancer treatment. Today, clinicians decide on the need for 
patients to undergo chemotherapies based on the stage and the invasiveness of the 
diagnosed tumors [4]. Hence, chemotherapies are targeted at eliminating cancer cells 
that could have resided in the patient even after physical removal of the tumor mass. 
According to the cancer stem cell (CSC) theory, residual cancer cells consisting of 
some CSCs will result in the repopulation of the entire tumor, resulting in metastasis 
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[5]. It is thus important to predict the efficacy of the chemotherapeutic treatment 
towards CSCs in order to improve the survival of the cancer patients [6]. 
DropArrayTM technology can be employed to screen against the cancer stem cells 
enriched from the patient to optimize the chemotherapeutic approach so as to 
maximize the chance of survival from cancer metastasis.        
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Chapter 6 – Conclusion 
 
Today, the ability to handle scarce cells while developing biologically relevant 
assays is the key challenge to modern cancer-drug discovery. Despite the ability to 
maximize the number of assay points through miniaturization technologies, the huge 
amount of cell loss during cell seeding in microfluidics platforms and microarrays 
makes screening against scarce biological samples such as cancer stem cells (CSCs) 
extremely challenging.  
We have developed a new microarray technique, DropArrayTM, which ensure 
minimum loss of precious samples during cell seeding. The DropArrayTM technology 
conducts assays on an array of hydrophilic spots generated by the 
polytetrafluoroethylene (PTFE) prints on a flat slide. By applying perfluorocarbon 
liquid (PFCL) to protect the hydrophobic PTFE layer from surface wetting during 
rinsing, each assay point on the DropArrayTM plate is self-contained, as in the 
conventional well plates. Hence, precious cells can be seeded directly onto the 
individual assay spots of the DropArrayTM plate to ensure negligible cell loss.   
Besides enabling cell-based assay for scarce samples, the DropArrayTM 
technology is designed to be compatible to the common laboratory equipment, such as 
microscopes, plate readers, robotic dispensers and standard pipettes. In addition, high-
content screening (HCS) assays can be conveniently miniaturized using the 
DropArrayTM technology, producing comparable data to the standard 96-well plates. 
The advantage of the DropArrayTM technology for studying scarce biological samples 
was demonstrated for cancer stem-like cells. The drug resistance characteristics of 
these cells were successfully elucidated.   
